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Brain tyrosinase overexpression implicates
age-dependent neuromelanin production
in Parkinson’s disease pathogenesis
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In Parkinson’s disease (PD) there is a selective degeneration of neuromelanin-containing
neurons, especially substantia nigra dopaminergic neurons. In humans, neuromelanin
accumulates with age, the latter being the main risk factor for PD. The contribution of
neuromelanin to PD pathogenesis remains unknown because, unlike humans, common
laboratory animals lack neuromelanin. Synthesis of peripheral melanins is mediated by
tyrosinase, an enzyme also present at low levels in the brain. Here we report that over-
expression of human tyrosinase in rat substantia nigra results in age-dependent production
of human-like neuromelanin within nigral dopaminergic neurons, up to levels reached in
elderly humans. In these animals, intracellular neuromelanin accumulation above a specific
threshold is associated to an age-dependent PD phenotype, including hypokinesia, Lewy
body-like formation and nigrostriatal neurodegeneration. Enhancing lysosomal proteostasis
reduces intracellular neuromelanin and prevents neurodegeneration in tyrosinase-
overexpressing animals. Our results suggest that intracellular neuromelanin levels may set
the threshold for the initiation of PD.
https://doi.org/10.1038/s41467-019-08858-y OPEN
1 Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)-Network Center for Biomedical Research in Neurodegenerative
Diseases (CIBERNED), 08035 Barcelona, Spain. 2 Telethon Institute of Genetics and Medicine (TIGEM), 80078 Naples, Italy. 3 Department of Neurology,
Tohoku University School of Medicine, Miyagi 980-8574, Japan. 4Department of Neurochemistry and Neuropharmacology, IIBB–CSIC, August Pi i Sunyer
Biomedical Research Institute (IDIBAPS)-Center for Networked Biomedical Research on Mental Health (CIBERSAM), 08036 Barcelona, Spain. 5 Neurological
Tissue Bank, Biobanc Hospital Clínic-IDIBAPS, 08036 Barcelona, Spain. 6 Institute of Neurology, Medical University of Vienna, 1090 Vienna, Austria.
7 Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, 08193 Barcelona, Spain. 8 Catalan Institution for Research and
Advanced Studies (ICREA), 08010 Barcelona, Spain. These authors contributed equally: Iria Carballo-Carbajal, Ariadna Laguna. Correspondence and
requests for materials should be addressed to M.V. (email: miquel.vila@vhir.org)
NATURE COMMUNICATIONS |          (2019) 10:973 | https://doi.org/10.1038/s41467-019-08858-y |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
In Parkinson’s disease (PD), neurons that contain the dark-brown cytoplasmic pigment neuromelanin (NM) are particu-larly susceptible to neurodegeneration1. Indeed, while PD
patients exhibit an abnormal accumulation of alpha-synuclein
(aSyn) protein in different brain regions, and even in peripheral
tissue2, neurodegeneration preferentially occurs within NM-
containing regions in these patients3–5. In contrast, neuronal
loss in non-melanized brain regions is either inconsistent, not
specific to PD, or secondary to the loss of interconnected NM-
containing neurons3–5. Such highly vulnerable NM-containing
brain regions include the substantia nigra pars compacta (SNpc),
where the loss of dopaminergic (DA) neurons therein leads to the
typical motor symptoms of the disease and constitutes the car-
dinal pathologic diagnostic criterion for PD. In the human SNpc,
which is the primary source of NM in the human brain, NM
levels are actually so high that this structure can be seen mac-
roscopically as a darkened area (hence the origin of the name
given to this brain region)6. NM is restricted to catecholamine-
producing regions and forms only in neurons. It first becomes
observable in the human SNpc at ~3 years of age and progres-
sively accumulates over time within the cells in which it has been
produced, as neurons apparently lack the mechanisms for
degrading or eliminating this pigment. As a consequence, intra-
cellular NM builds up with age until occupying most of the
neuronal cytoplasm7. Importantly, aging is the main risk factor
for developing PD8.
DA-producing cell groups of the normal human midbrain
differ markedly from each other in terms of the percentage of
NM-pigmented neurons they contain1,9,10. In PD, the estimated
cell loss in these cell groups directly correlates with the percentage
of NM-pigmented neurons normally present in them1,9,10. Like-
wise, within each cell group in PD brains, there is greater relative
sparing of weakly pigmented than of strongly melanized
neurons1,9,10. Also, classical Lewy bodies (LB), i.e. aSyn-
containing intracytoplasmic inclusion bodies that represent the
pathological hallmark of the disease, as well as their presumed
precursor structures, pale bodies (PB), typically appear within the
intracellular areas of the cytoplasm in which NM accumulates
and form in close physical association with this pigment11. Along
this line, studies in human brains have shown that aSyn redis-
tributes to the lipid component of NM at early PD stages12 and
that aSyn becomes entrapped within NM granules extracted from
PD, but not control, brains13. Further linking PD neuropathology
with NM, PD-linked neuroinflammatory changes are highly
localized within NM-containing areas and are barely observed in
non-melanized regions, such as the cortex, despite the latter
exhibiting PD-related aSyn depositions14.
According to the above observations, PD pathogenesis appears
inextricably linked to the presence of NM. However, despite the
close and long-established association between NM and PD, the
physiological significance of NM and its potential contribution to
PD pathogenesis remain unknown. The current lack of knowl-
edge about the role of NM both in healthy subjects and in PD
patients lies in the fact that, in contrast to humans, laboratory
animal species commonly used in experimental research, such as
rodents, lack NM15. In fact, the great abundance of NM in the
brainstem is unique to humans, as macroscopic dark pigmenta-
tion of this brain area is not observed in other animal species16.
Consequently, a factor so intimately linked to PD such as NM has
been surprisingly neglected so far in experimental in vivo para-
digms of the disease. To address this major limitation, in the
present study we generate the first rodent model of age-
dependent human-like NM production in SNpc DA neurons at
levels up to those reached in elderly humans. Using this unique
model, we show that progressive intracellular NM accumulation
above a specific threshold is associated with a PD phenotype.
Results
Age-dependent NM formation in tyrosinase-overexpressing
rats. The mechanism of synthesis of NM is poorly understood,
but it is generally accepted that NM is formed as an inert cellular
by-product of DA synthesis produced by simple non-enzymatic
DA autoxidation17. In contrast, it is well-established that the
synthesis of peripheral melanins (e.g. skin and hair), which occurs
within specialized cells (i.e. melanocytes), results from an enzy-
matically driven biosynthetic pathway initiated with the hydro-
xylation of L-tyrosine to L-DOPA, followed by the oxidation
of L-DOPA to the melanin precursor DOPAquinone, in which
tyrosinase is the key, rate-limiting enzyme18,19. Remarkably,
tyrosinase expression and activity are not apparently restricted
to melanocytes but have also been observed, although at low
levels, in the brain, including human SNpc20–22 (Supplementary
Figure 1). In addition, tyrosinase is also able to oxidize the
catechol ring of DA, which is an essential event required for NM
synthesis19. However, whether brain tyrosinase may actually
contribute to NM synthesis is currently unknown. Here we
assessed what are the consequences of overexpressing tyrosinase
in the SNpc of rodents.
Adult rats received a single unilateral stereotaxic injection of an
adeno-associated viral (AAV) vector expressing human tyrosinase
(hTyr) above the right SNpc (Fig. 1a). By 2–4 weeks (w) post-
AAV-hTyr injection, up to ~80–90% of ipsilateral SNpc DA
neurons were transduced and expressed the hTyr protein (Fig. 1b).
By 2 months (m) post-AAV-hTyr injection, the ipsilateral
SNpc from these animals could be visualized macroscopically,
in the absence of any staining, as a darkened brown area, similar
to human melanized SNpc tissue (Fig. 1c). In contrast, the
contralateral SNpc from the same animals could not be detected
macroscopically, as rodents lack NM (Fig. 1c). Similar to humans,
ipsilateral SNpc from AAV-hTyr-injected animals could also
be detected macroscopically as a hyperintense area by NM-
sensitive high-resolution T1-weighted magnetic resonance ima-
ging (Fig. 1d). Optical microscopy visualization confirmed that
the darkened SNpc area in AAV-hTyr-injected rats corresponded
to the presence of an intracellular dark-brown fine granular
pigment analogous to human NM within ipsilateral SNpc
neurons (Fig. 1e). Virtually all (~97%) hTyr-expressing SNpc
DA neurons from AAV-hTyr-injected animals produced NM
(Supplementary Figure 2). As in humans, NM from AAV-hTyr-
injected rats stained prominently with the melanin marker
Masson-Fontana, which reflects the ability of NM to chelate
metals (Fig. 1f). Ultrastructural examination by electron micro-
scopy identified NM granules from AAV-hTyr-injected rats as
membrane-delimited autophagic structures with an electron-
dense matrix of irregular shape and size, associated with
characteristic lipid droplets, equivalent to what has been
described in humans23 (Fig. 1g). Within the SNpc, NM pigment
in AAV-hTyr-injected rats was restricted to TH−immunopositive
DA neurons (Supplementary Figure 2), thereby mimicking the
pattern of human NM distribution within catecholamine-
producing neurons6.
In human SNpc DA neurons, NM is continuously produced
throughout life and progressively accumulates with age until it
occupies a major portion of the neuronal cytoplasm24. Similarly,
quantification of intracellular NM optical density in SNpc
neurons of AAV-hTyr-injected rats, which reflects the actual
concentration of NM7,10, revealed that intracellular NM levels
steadily increase in the SNpc of these animals over time, from 0.5
up to 24 m post-AAV-hTyr injection, until occupying most of the
neuronal cytoplasm (Fig. 2a, b). In ~1–2 m, intracellular NM in
AAV-hTyr-injected rats reached levels equivalent to those in
post-mortem SNpc tissue from elderly (~80 years old) human
control subjects (Fig. 2b, c). In ~2–4 m, AAV-hTyr-injected rats
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exhibited intracellular NM levels equivalent to those in post-
mortem SNpc tissue from (i) subjects with incidental LB disease
(ILBD), i.e. clinically healthy individuals exhibiting LB pathology
at autopsy who are considered to represent early, presymptomatic
stages of PD, and (ii) established PD patients (Fig. 2b, c), in both
of which intracellular NM levels appeared significantly higher
than those from age-matched control subjects (Fig. 2c; see also
Supplementary Table 1).
Overall, these results show that hTyr expression in rat SNpc
leads to the production of human-like NM within SNpc DA
neurons. As in humans, intracellular NM levels in these animals
steadily increase over time, reaching first levels equivalent to
those of elderly human brains and further increasing up to levels
attained in pre-PD subjects and PD patients.
Progressive PD-like neurodegeneration in NM-producing rats.
Using our newly generated NM-producing rats, we next assessed
whether age-dependent intracellular NM accumulation, up to
levels reached in elderly subjects and ILBD/PD cases, may be
associated to compromised cell viability. Stereological cell counts
of SNpc TH-positive neurons in AAV-hTyr-injected rats revealed
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Fig. 1 Human-like NM production in AAV-hTyr-injected rats. a Schematic representation of the site of AAV-hTyr unilateral stereotaxic injection above the
SNpc of the rat brain. b Representative photomicrographs of a 30-μm-thick ipsilateral SNpc section from an AAV-hTyr-injected rat (1 m post-AAV
injection) immunostained for TH (red) and hTyr (green). Scale bar, 500 μm. c Left, representative unstained AAV-hTyr-injected rat brain (2m post-AAV
injection) mounted in a cryostat in which ipsilateral SNpc can be detected macroscopically as a brown, darkened area (dashed outline). A hole was made in
the contralateral hemisphere as anatomical reference. Right, representative unstained midbrain from a 62-year-old human control subject (Hu) in which
the SNpc can be detected macroscopically (bilateral dashed outlines). d Representative NM-sensitive high-resolution T1-weighted magnetic resonance
imaging of an AAV-hTyr-injected rat brain at 2 m post-AAV injection (left, ex-vivo) and of a 59-year-old human control brain (Hu, right, in vivo). SNpc can
be detected as a unilateral (AAV-hTyr-injected rodent) or bilateral (human) hyperintense area (dashed outlines). e Representative photomicrograph of an
unstained 30-μm-thick ipsilateral SNpc section from an AAV-hTyr-injected rat (2 m post-AAV injection) in which NM is shown in brown. Inset, high
magnification of a melanized neuron. Scale bars, 100 μm and 12.5 μm (inset). f Representative photomicrographs of Masson-Fontana melanin staining
(NM in dark brown) in 5-μm-thick SNpc sections from an AAV-hTyr-injected rat at 2 m post-AAV injection (left) and an 80-year-old human control
subject (Hu, right). Scale bars, 25 μm (left) and 12.5 μm (right). g Representative electron micrograph of NM granules in the ipsilateral SNpc of an
AAV-hTyr-injected rat at 4 m post-AAV injection (left) and a 75-year-old human control subject (Hu, right). NM pigment is detected as an electron dense
matrix. Characteristic associated lipid droplets are indicated with asterisks. Scale bars, 500 nm
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Fig. 2 Age-dependent NM accumulation in AAV-hTyr-injected rats. a Hematoxylin-eosin (H&E)-stained brain sections showing progressive intracellular
NM accumulation (brown) within ipsilateral SNpc DA neurons from AAV-hTyr-injected rats. Scale bar, 12.5 μm. b Quantification of intracellular NM optical
density in ipsilateral SNpc DA neurons of AAV-hTyr-injected rats. *p < 0.05, compared to 0.5 m; #p < 0.05, compared to 1 m; §p < 0.05, compared to 2&4
m. c Left, quantification of intracellular NM optical density in post-mortem SNpc sections from elderly human (average 80 years old) control subjects, age-
matched ILBD subjects and age-matched idiopathic PD patients. *p < 0.05, compared to control subjects. Right, H&E-stained human brain sections. Scale
bar, 12.5 μm. In b, c values are mean ± SEM. In b, n= 163 neurons from n= 7 rats (0.5 m), n= 136 neurons from n= 5 rats (1 m), n= 174 neurons from n=
5 rats (2 m), n= 162 neurons from n= 7 rats (4m), n= 172 neurons from n= 6 rats (12 m), n= 179 neurons from n= 6 rats (24m). In c, n= 1436
neurons from n= 6 control subjects, n= 640 neurons from n= 3 ILBD subjects, n= 644 neurons from n= 10 PD subjects. See Supplementary Table 1 for
additional information on the human subjects used for the analyses in c. Statistical analyses: ANOVA on ranks; Dunn’s post-hoc test. Photomicrographs
correspond to 5-μm-thick sections
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a progressive, age-dependent loss of TH-positive SNpc neurons,
starting by 4 m post-AAV-hTyr injection (Fig. 3a, b). Progressive
loss of SNpc TH-positive neurons in AAV-hTyr-injected rats was
accompanied by a reduction of striatal DA TH-positive fibers, as
measured by optical densitometry (Fig. 3c). Loss of nigrostriatal
DA fibers in AAV-hTyr-injected rats was accompanied by
decreased striatal DA levels, as measured by high-performance
liquid chromatography (HPLC) (Supplementary Table 2), and
abnormally enlarged nigrostriatal TH-positive nerve terminals
(Supplementary Fig. 3).
Similar to PD brains, NM-laden neurons from AAV-hTyr-
injected rats also exhibited an early phenotypic loss of TH
expression, as indicated by an increased percentage of TH-
immunonegative neurons within the total population of NM-
containing neurons (Fig. 3d). TH-immunonegative pigmented
neurons are believed to represent dysfunctional/dying SNpc DA
neurons1. To distinguish between reduced TH expression and
actual cell death, we performed stereological cell counts of total
SNpc DA neurons (including TH-immunopositive and TH-
immunonegative melanized SNpc neurons), which confirmed a
progressive loss of SNpc DA neurons in AAV-hTyr-injected rats
(Fig. 3e). In parallel to the loss of melanized SNpc neurons, there
was a progressive depigmentation of the SNpc in AAV-hTyr-
injected rats, as it occurs in PD patients (Fig. 3a, right panel).
Correlation analyses in AAV-hTyr-injected rats confirmed a
strong positive and significant correlation between intracellular
NM levels and SNpc DA neurodegenerative changes (Supple-
mentary Figure 3). In contrast, no degeneration of non-DA, non-
melanized neighboring gamma-aminobutyric acid nigral neurons
was observed in AAV-hTyr-injected rats, as indicated by the
preservation of the ipsilateral gamma-aminobutyric acidergic
nigrotectal pathway in these animals (Supplementary Figure 4),
despite this region being systematically transduced with hTyr in
AAV-hTyr-injected animals, due to its proximity to the site of the
AAV-hTyr injection (Supplementary Figure 2). Relevant to
humans, these neurons do not degenerate in PD patients3 and
do not contain NM in humans, as they do not use a
catecholaminergic NM precursor as neurotransmitter. In addi-
tion, no nigrostriatal DA degeneration was observed in aging
non-melanized contralateral SNpc from AAV-hTyr-injected rats
(Fig. 3b, e) nor in aging non-melanized ipsilateral SNpc from
AAV-empty vector (EV)-injected or vehicle-injected control rats
(Supplementary Figure 4).
We next determined whether the neurodegenerative changes
observed in AAV-hTyr-injected rats were accompanied by
functional alterations. At different time-points post-AAV-hTyr
injections, from 0.5 up to 24 m, rats were subjected to behavioral
analyses with the cylinder test, which allows asymmetrical
alterations in nigrostriatal DA function to be detected25.
Concomitant with the ipsilateral degeneration of NM-laden SNpc
neurons reported above, AAV-hTyr-injected rats exhibited
contralateral forepaw hypokinesia, as indicated by reduced
contralateral forepaw use, compared to AAV-EV-injected animals
(Fig. 4a). These motor alterations started by 2 m post-AAV-hTyr
injection, thus coinciding with the first signs of striatal axonal
damage (i.e. axonal swelling, Supplementary Figure 3) and
preceding nigrostriatal neurodegeneration in these animals
(Fig. 3a–e). As motor impairment preceded overt neuron cell
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Fig. 3 Progressive nigrostriatal degeneration in AAV-hTyr-injected rats. a Left, ipsilateral SNpc and striatum (inset) sections immunostained for TH (blue).
Right, ipsilateral SNpc sections stained with Masson-Fontana (NM in dark brown; inset, higher magnification of melanized neurons). Scale bars, 300 μm
(left), 2 mm (left inset), 150 μm (right), and 12.5 μm (right inset). b Stereological cell counts of SNpc TH-positive neurons in AAV-hTyr-injected rats.
*p < 0.05, compared to respective contralateral (non-injected) side; #p≤ 0.05, compared to ipsilateral naive, 0.5, 1, and 2m; §p < 0.05, compared to
ipsilateral 4 and 12m (two-way ANOVA; Student–Newman–Keuls post-hoc test). c Optical densitometry of striatal TH-positive fibers in AAV-hTyr-
injected rats. *p < 0.05, compared to 0.5 m; #p < 0.05, compared to naive (ANOVA on ranks; Dunn’s post-hoc test). d Stereological cell counts of SNpc
NM+ /TH+ (white arrowhead) and NM+ /TH− (black arrowhead) neurons vs total NM+ neurons in AAV-hTyr-injected rats. *p < 0.05, compared
to 0.5 m; #p < 0.05, compared to 1 and 2m; §p < 0.05, compared to 12 m (one-way ANOVA; Student–Newman–Keuls post-hoc test). e Stereological
cell counts of total SNpc DA neurons (including TH-immunopositive and TH-immunonegative melanized neurons) in AAV-hTyr-injected rats. *p < 0.05,
compared to respective contralateral side; #p < 0.05, compared to ipsilateral naive, 0.5 and 1 m; §p < 0.05, compared to ipsilateral 2, 4, and 12m (two-way
ANOVA; Student–Newman–Keuls post-hoc test). In all panels, values are mean ± SEM. In a–e, n= 6 (Naïve), n= 8 (0.5 m), n= 7 (1 m), n= 5 (2m), n= 8
(4m), n= 7 (12 m), and n= 6 (24m). Photomicrographs correspond to 5-μm-thick sections
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death in AAV-hTyr-injected rats, we next evaluated whether
striatal DA function was already impaired in these animals at
such early stages. Striatal DA release following chemical or
electrical stimulation was measured by microdialysis in the
ipsilateral striatum of vehicle- and AAV-hTyr-injected rats. At
baseline, no differences in extracellular striatal DA concentration,
measured by HPLC, were observed between control- and AAV-
hTyr-injected freely moving rats, indicating that hTyr expression
per se does not alter basal DA neurotransmission (Fig. 4b).
Stimulation of striatal DA release by local amphetamine
administration induced concentration-dependent increases of
extracellular striatal DA in both control- and AAV-hTyr-injected
rats, but this effect was much less pronounced in the latter group
of animals (Fig. 4b). Similarly, when stimulated with the
depolarizing agent veratridine, striatal DA release was also less
prominent in AAV-hTyr-injected rats compared to control-
injected animals (Fig. 4b). We next assessed striatal DA release
induced by electrical stimulation of the ipsilateral medial
forebrain bundle (MFB) via an electrode implanted in these
animals. Similar to freely moving rats, no differences in baseline
extracellular DA levels in the striatum were detected between
control- and AAV-hTyr-injected anaesthetized animals (Fig. 4c).
However, following electrical stimulation of the MFB, AAV-
hTyr-injected animals exhibited a markedly reduced release of
striatal DA compared to control-injected rats (Fig. 4c). These
results indicate that synaptic DA release by NM-laden nigros-
triatal neurons is impaired before any overt SNpc cell loss has
occurred, as is believed to be the case in PD patients26,27.
To further corroborate the occurrence of a synaptic failure in
these animals, we also measured the striatal densities of dopamine
transporter (DAT) and vesicular monoamine transporter 2
(VMAT2) immunopositive fibers in AAV-hTyr-injected rats at
different times post-AAV-hTyr injections, from 0.5 up to 24 m
(Supplementary Figure 3). Striatal DAT-positive fibers in AAV-
hTyr-injected rats exhibited an earlier and more extensive loss
than striatal TH-positive fibers, starting by 2 m post-AAV-hTyr
injections (i.e. at the time of neuronal dysfunction but before the
occurrence of overt neurodegeneration in these animals) and
reaching up to a 90% striatal depletion. In contrast, striatal
VMAT2 levels were significantly decreased by 12 m post-AAV-
hTyr injections and reached a 50% reduction. These results
concur with equivalent neuroimaging in vivo analyses in PD
patients, in which neuroimaging reductions in DAT striatal
density (i.e. by [11C]d-threo-methylphenidate PET or 123I-2β-
carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)-nortro-
pane SPECT) can be detected at early stages of the disease,
including in pre-motor idiopathic REM sleep behavior
disorder patients28–30 and pre-symptomatic LRRK2 non-
manifesting carriers31–34. In contrast, neuroimaging reductions
in VMAT2 striatal density (i.e. by [11C]( ± )dihydrotetrabenazine
PET) only become consistent once the disease is fully estab-
lished35–38, probably as a compensatory mechanism to maintain
extracellular levels of DA at early disease stages and thus delay the
onset of parkinsonian symptoms37.
Concomitant with SNpc DA neurodegeneration, abundant
extracellular NM aggregates, released from dying neurons, were
detected in the SNpc of AAV-hTyr-injected rats, as it is usually
observed in aged and PD brains39 (Fig. 5a, c). Extracellular NM
was associated with sustained microglial/macrophage activation
(Fig. 5b, d), with NM fragments as well as entire NM-filled
residual neurons being surrounded by, or contained within,
activated microglia/macrophages (Fig. 5b–e). This phenomenon,
known as neuronophagia, is commonly seen in post-mortem aged
and PD brains39 (Fig. 5c) and is indicative of an active, ongoing
neurodegenerative process40. Double immunofluorescence ana-
lyses revealed that neuronophagia was directed not only at
extracellular NM debris but also, in some instances, at
dysfunctional/dying NM-laden neurons that have lost their TH
phenotype (Fig. 5e). In contrast, no neuronophagia was detected
surrounding morphologically intact, apparently healthy, TH-
positive NM-laden cells (Fig. 5e). Ultimately, and analogous to
PD brains, NM-filled microglia from AAV-hTyr-injected rats
appeared to migrate to blood vessels to exit the brain along with
the NM pigment, as revealed by abundant perivascular NM in
these animals (Fig. 5a, c, f). No neuroinflammatory changes were
observed in the SNpc of AAV-EV-injected control rats nor in the
contralateral (non-melanized) SNpc of AAV-hTyr-injected rats
(Supplementary Figure 4).
DA oxidation to quinones is an essential event required for
NM synthesis41 (Supplementary Figure 5). Because DA-derived
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Fig. 4 Early dopaminergic dysfunction in AAV-hTyr-injected rats. a Contralateral forepaw use in AAV-hTyr- and AAV-EV-injected rats, as assessed with
the cylinder test. *p≤ 0.05, compared to AAV-EV-injected animals at the same time-point; #p < 0.05, compared to 0.5 m AAV-hTyr animals (two-way
ANOVA; Student–Newman–Keuls post-hoc test). b Striatal DA release in AAV-hTyr- and vehicle-injected rats measured by microdialysis in the ipsilateral
striatum following local amphetamine (left) or veratridine (right) administration by reverse-dialysis. *p < 0.05, compared to vehicle-injected animals
(ANOVA for repeated measures of the DA values during the specified time periods; Tukey’s post-hoc test). Baseline DA concentration (fmol/fraction-
20min): amphetamine experiments, 82.83 ± 19.16 (vehicle) vs 94.38 ± 21.82 (AAV-hTyr); veratridine experiments, 25.52 ± 4.33 (vehicle) vs 29.93 ± 6.46
(AAV-hTyr). c Striatal DA release in AAV-hTyr- and vehicle-injected rats measured by microdialysis in the ipsilateral striatum following electrical
stimulation of the MFB for 10-min periods under S1 and S2 conditions (S1, 2.0 Hz, 0.1 mA, 0.2 ms; S2, 10 Hz, 0.1 mA, 1 ms). *p < 0.05, compared to
stimulated AAV-hTyr-injected rats (ANOVA for repeated measures; Tukey’s post-hoc test). Baseline DA concentration (fmol/fraction-10 min): 16.8 ± 2.38
(vehicle) vs 23.02 ± 6.37 (AAV-hTyr). In all panels, values are mean ± SEM. In a, AAV-EV-injected rats n= 20 (0.5 m), n= 20 (1 m), n= 9 (2 m), n= 9
(3m), n= 8 (6m), n= 12 (12 m), n= 4 (24m); and AAV-hTyr-injected rats n= 29 (0.5 m), n= 8 (1 m), n= 21 (2 m), n= 14 (3 m), n= 7 (6m), n= 14
(12 m), n= 6 (24m). In b, c, experiments were performed at 1-2 m post-AAV injection. In b, n= 6 vehicle-injected, n= 6 AAV-hTyr-injected rats+
Amphetamine and n= 8 AAV-hTyr-injected rats+Veratridine. In c, n= 4 animals per group
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08858-y ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:973 | https://doi.org/10.1038/s41467-019-08858-y |www.nature.com/naturecommunications 5
quinones can be potentially toxic to DA neurons42–45, we next
determined whether the neurodegenerative process observed in
our NM-producing rats could be attributed to hTyr-mediated
production of potentially toxic oxidized DA species. To address
this issue, we developed a method to directly measure DA
oxidation in AAV-hTyr-injected rats by ultra-performance liquid
chromatography-tandem mass spectrometry (UPLC-MS/MS).
Levels of oxidized DA were measured in both ipsilateral (i.e.
melanized) and contralateral (i.e. non-melanized) ventral mid-
brains of AAV-hTyr-injected rats, at different times post-AAV
injection: 1 m (i.e. before the occurrence of NM-linked neuronal
dysfunction in these animals), 2 m (i.e. at the onset of neuronal
dysfunction but before the occurrence of neurodegeneration) and
4 m (i.e. once neurodegeneration is established). No significant
changes were detected between ipsilateral and contralateral
ventral midbrain levels of oxidized DA at any of the times
analyzed (Supplementary Figure 5), therefore arguing against a
major significant contribution of oxidized DA species in the
pathological changes observed in AAV-hTyr-injected rats.
Further supporting this concept, we did not detect significant
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Fig. 5 Extracellular NM and neuronophagia in AAV-hTyr-injected rats. a Left, extracellular NM aggregates in ipsilateral SNpc from AAV-hTyr-injected rats.
*p < 0.05, compared to 0.5&1 m; #p < 0.05, compared to 2m (one-way ANOVA; Student–Newman–Keuls post-hoc test). Middle, hematoxylin-eosin
(H&E)-stained ipsilateral SNpc sections from AAV-hTyr-injected rats (4m). Scale bar, 25 μm. Right, Pearson correlation analysis between total SNpc DA
neurons and extracellular NM. b Left, neuronophagia in ipsilateral SNpc from AAV-hTyr-injected rats. *p < 0.05, compared to 0.5 m (ANOVA on ranks;
Dunn’s post-hoc test). Middle, H&E-stained ipsilateral SNpc sections from AAV-hTyr-injected rats (4 and 12m). Scale bar, 62.5 μm. Right, Pearson
correlation analysis between extracellular NM and neuronophagia. c H&E-stained midbrain sections from PD post-mortem brains and AAV-hTyr-injected
rats. Scale bars, 12.5 μm (top & bottom) and 25 μm (middle). d Ipsilateral SNpc sections from AAV-hTyr-injected rats (2–12 m) immunostained for the
microglial marker Iba1 (blue, top) or the macrophage marker CD68 (blue, bottom). Scale bars, 375 μm (Iba1, low magnification), 12.5 μm (Iba1, high
magnification), 150 μm (CD68, low magnification), and 25 μm (CD68, high magnification). e Ipsilateral SNpc sections from AAV-hTyr-injected rats (4m)
immunostained for TH (red) and Iba1 (green) and co-stained with the nuclear marker Hoechst (blue). Arrowheads, intact TH-positive NM-laden neurons;
single arrow, neuronophagia directed at extracellular NM debris; double arrows, neuronophagia directed at a TH-immunonegative NM-laden neuron. Scale
bar, 25 μm. f Top, Ipsilateral SNpc section from an AAV-hTyr-injected rat (4 m) immunostained with Iba1 (green) and astrocytic marker GFAP (purple), co-
stained with blood vessel marker tomato lectin (red) and Hoechst (blue). Arrowheads, microglial cells carrying NM towards blood vessels. Arrow,
perivascular NM. Scale bar, 25 μm. Bottom, Pearson correlation analysis between neuronophagia and perivascular NM. In a, b histograms, values are
mean ± SEM. In a, n= 8 (0.5 m), n= 7 (1 m), n= 5 (2 m), n= 8 (4m), n= 7 (12 m), n= 6 (24m). In b, n= 6 (0.5 m), n= 5 (1 m), n= 5 (2m), n= 7 (4m),
n= 6 (12m), n= 6 (24m). For Pearson correlation analyses each point represents the average value for the corresponding parameter at any given time
post-AAV-hTyr injection (0.5, 1, 2, 4, 12, and 24m). BF bright-field. In all panels, unstained NM appears as brown. Photomicrographs correspond to 5-μm-
thick sections
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alterations in DA metabolism in these animals, either preceding
or at the onset of neurodegeneration, as reflected by unchanged
levels of DA and other DA metabolites in their ventral midbrains
(Supplementary Figure 5).
Our results reveal that age-dependent NM production within
SNpc DA neurons in AAV-hTyr-injected rats is associated with
neuronal dysfunction and progressive nigrostriatal neurodegen-
eration, equivalent to that occurring in PD patients46, once a
certain threshold of intracellular NM accumulation is reached.
Remarkably, the intracellular NM levels above which AAV-hTyr-
injected rats started exhibiting functional alterations (by 2 m) and
overt neurodegeneration (by 4 m) were equivalent to those
observed in ILBD subjects and PD patients (Fig. 2b, c), thus
allowing a specific pathogenic threshold for intracellular NM
accumulation to be defined (see dashed red lines in Fig. 2b, c).
These results are consistent with intracellular NM levels setting a
threshold for the initiation of PD-related neurodegeneration.
PD-like inclusion formation in NM-producing rats. In addition
to neurodegeneration, ipsilateral NM-laden SNpc DA neurons from
AAV-hTyr-injected rats also exhibited intracellular inclusion bodies
typical of human post-mortem aged and PD brains, including
nuclear Marinesco bodies (MB) and cytoplasmic PB and LB-like
inclusions (Fig. 6). Inclusion body formation in these animals: (i)
was restricted to NM-containing neurons, (ii) peaked at 2m post-
AAV-hTyr injection, thus coinciding with functional alterations
and preceding neurodegeneration in these animals, and (iii) was
substantially reduced by 4m and onwards, once neurodegeneration
was already established (Fig. 6a, b).
MB are spherical eosinophilic nuclear inclusions found in
pigmented neurons of the human SNpc, the incidence of
which increases with advancing age47. Similar to humans47,
one or several MB were detected in the nucleus of pigmented
SNpc neurons from AAV-hTyr-injected rats (Fig. 6c, d, f). In
these animals, MB were intensely immunopositive for p62, a
common component of neuropathological inclusions, and
ubiquitin (Fig. 6f), as it has been previously reported in
humans47. No MB were found in non-pigmented neurons
from AAV-hTyr-injected rats. Concomitant with the occur-
rence of MB, NM-laden neurons from AAV-hTyr-injected rats
also exhibited cytoplasmic PB and LB-like inclusions, often
within the same cell, as is commonly seen in PD brains47
(Fig. 6c–i). No cytoplasmic inclusions were found in non-
pigmented neurons from these animals. PB are identified as
weakly or non-eosinophilic cytoplasmic areas of varied
morphologies that displace NM, lacking the spherical and
compact appearance of LB-like structures (Fig. 6d). As in PD,
PB and LB-like inclusions from AAV-hTyr-injected rats were
immunopositive for p62 and, in some instances, for aSyn
(both full length and hyperphosphorylated) and ubiquitin
(Fig. 6e, g–i and Supplementary Figure 6). This is consistent
with previous studies in human PD brains reporting a
selective, early, and consistent incorporation of p62 into both
PB and LB, suggesting an important role for p62 in their
formation, in contrast to a less consistent and less selective
accumulation of ubiquitin within these cytoplasmic inclu-
sions47. Cytoplasmic inclusions in AAV-hTyr-injected rats
emerged within NM-filled areas, either overlapping with or
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Fig. 6 PD-type inclusion formation in AAV-hTyr-injected rats. a Quantification of NM-laden neurons with p62-positive intranuclear Marinesco bodies (MB)
in ipsilateral SNpc from AAV-hTyr-injected rats. *p < 0.05, compared to 0.5 m (ANOVA on ranks; Dunn’s post-hoc test). b Quantification of NM-laden
neurons with p62-positive total intracytoplasmic inclusion bodies (left) and pale bodies (PB) and/or Lewy body (LB)-like p62-positive inclusions (right) in
ipsilateral SNpc from AAV-hTyr-injected rats. Left, *p < 0.05, compared to 0.5, 1, 4, 12, and 24m (one-way ANOVA; Student–Newman–Keuls post-hoc
test). Right, *p < 0.05, compared to PB at 0.5, 4, 12, and 24m; #p < 0.05, compared to LB-like inclusions at 0.5, 1, 4, and 24m (two-way ANOVA; Holm-
Sidak post-hoc test). c–eMidbrain sections from PD post-mortem brains (top) and AAV-hTyr-injected rats (bottom) exhibiting MB (c, white arrowheads),
PB (d, blue arrowheads) and LB-type aSyn-positive inclusions (e, arrows). In c, d, Hematoxylin-eosin (H&E) staining. In e, aSyn immunostaining (in blue).
Scale bars, 12.5 μm. f Ipsilateral SNpc sections from AAV-hTyr-injected rats exhibiting NM-laden neurons with MB (white arrowhead) detected by
immunofluorescence with p62 (red) and ubiquitin (Ub, green). Nuclei are stained with Hoechst (blue). Scale bar, 12.5 μm. g Ipsilateral SNpc sections from
AAV-hTyr-injected rats exhibiting NM-laden neurons with p62-positive multipunctate cytoplasmic inclusions (yellow arrowhead), PB (blue arrowhead)
or LB-like inclusions (arrows). Scale bar, 12.5 μm. h Ipsilateral SNpc section from an AAV-hTyr-injected rat exhibiting a NM-laden neuron with an
intracytoplasmic LB-like inclusion immunopositive for p62 (red), aSyn (purple) and ubiquitin (Ub, green). Scale bar, 12.5 μm. i Ipsilateral SNpc section from
an AAV-hTyr-injected rat immunostained for p62 (red) and TH (purple) in which a NM-laden neuron containing both a PB (blue arrowhead) and a MB
(white arrowhead) exhibits decreased TH immunostaining (asterisk). Nuclei are stained with Hoechst (blue). Scale bar, 25 μm. In a, b, values are mean ±
SEM. n= 8 (0.5 m), n= 5 (1 m), n= 6 (2 m), n= 5 (4m), n= 6 (12m), n= 5 (24m). Ub ubiquitin, BF bright-field. In all panels, unstained NM appears
as brown. Photomicrographs correspond to 5-μm-thick sections
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displacing NM granules, and often appeared as early multiple
punctate small aggregates immunopositive for p62 that
seemed to progressively coalesce into more compacted LB-
like spherical structures (Fig. 6g), as similarly reported in
post-mortem PD brains47.
Taken together, our results show that intracellular NM
accumulation is associated with the formation of PD-like neuronal
inclusions in AAV-hTyr-injected rats. While the mechanism and
significance of inclusion body formation in PD remain unknown,
the temporal pattern of inclusion formation in AAV-hTyr-injected
rats (i.e. preceding neurodegeneration and decreasing in parallel
with neuronal death) suggests that inclusion-containing neurons are
those that preferentially degenerate in these animals. In agreement
with this, the number of neuronal inclusions in PD brains at
advanced stages of the disease is much lower than that observed in
early PD cases14, as it occurs in AAV-hTyr-injected rats. In
addition, in both humans48 and AAV-hTyr-injected rats (Fig. 6i),
inclusion-containing neurons often exhibit decreased intracellular
TH levels, which reflects neuronal dysfunction at early stages of
neurodegeneration1. Consistent with this, inclusion formation in
AAV-hTyr-injected rats peaked at the onset of functional
alterations (i.e. impaired DA release and hypokinesia) in these
animals. Our results indicate that PD-type inclusion body
formation reflects a pathologic process related or contributing to
PD-linked neuronal dysfunction and degeneration.
aSyn is dispensable for NM-linked PD pathology. Given the
presence of PD-like aSyn-positive inclusions in NM-producing
rats and the potential pathogenic role attributed to aSyn aggre-
gation in PD, we next assessed whether NM-linked PD-like
pathology in AAV-hTyr-injected animals was dependent on aSyn.
This question was addressed by inducing NM production with
AAV-hTyr in the SNpc of aSyn-deficient mice (Fig. 7a). Because
aSyn has been reported to be able to interact with tyrosinase49
and to modulate ultra-violet radiation-induced melanin synthesis
in melanoma cells50, we first determined whether the lack of aSyn
in aSyn-deficient mice could interfere with AAV-hTyr-induced
production of NM in these animals. Ruling out this possibility,
intracellular NM levels within AAV-hTyr-injected SNpc neurons
were comparable between wild-type (WT) and aSyn-deficient
mice at 6 m post-AAV-hTyr injection (Fig. 7b). By that time, WT
and aSyn-deficient mice exhibited intracellular NM levels similar
to the pathogenic threshold of intracellular NM accumulation
defined above for rats and humans (Fig. 7b). We next assessed
whether the absence of aSyn in aSyn-deficient mice may
prevent or attenuate the formation of PD-like cytoplasmic
inclusions within NM-laden neurons in AAV-hTyr-injected mice.
At 2 m post-AAV-hTyr injections (i.e. at the peak of inclusion
formation defined in AAV-hTyr-injected rats), NM-laden SNpc
neurons from WT mice exhibited p62-immunopositive PB and
LB-like inclusions at levels equivalent to those observed in AAV-
hTyr-injected rats (Fig. 7c and Supplementary Figure 6). Unex-
pectedly, NM-laden SNpc neurons from AAV-hTyr-injected
aSyn-deficient mice exhibited similar p62-immunopositive
inclusions at levels comparable to those of WT animals
(Fig. 7c), indicating that the lack aSyn did not prevent the
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Fig. 7 Dispensability of aSyn for PD-like inclusion formation and neurodegeneration linked to NM accumulation. a Schematic representation of the site of
AAV-hTyr unilateral stereotaxic injection above the SNpc of aSyn knockout (KO) and wild-type (WT) mice. b Top, representative photomicrographs of
NM-laden neurons in hematoxylin-eosin (H&E)-stained ipsilateral SNpc brain sections from AAV-hTyr-injected aSyn KO and WT mice at 6 m post-AAV
injection. Scale bar, 12.5 μm. Bottom, quantification of intracellular NM optical density in ipsilateral SNpc DA neurons of AAV-hTyr-injected aSyn KO and
WT mice. p= 0.879 (two-tailed t-test). c Top, ipsilateral SNpc sections from AAV-hTyr-injected aSyn KO and WT mice exhibiting NM-laden neurons
with p62-positive (red) PB (arrowhead) and LB-like inclusions (arrow) at 2 m post-AAV injection. aSyn immunofluorescence is shown in green. Scale bar,
12.5 μm. Bottom, quantification of NM-laden neurons with p62-positive PB or LB-like inclusions in AAV-hTyr-injected aSyn KO and WT mice at 2 m post-
AAV injection. p= 0.866 (two-way ANOVA). d Top, optical densitometry of striatal TH-positive fibers in AAV-hTyr-injected aSyn KO and WT mice at 6m
post-AAV injection. *p < 0.05, compared to respective contralateral (non-injected) side (two-way ANOVA; Student–Newman–Keuls post-hoc test).
Bottom, stereological cell counts of SNpc TH-positive neurons in AAV-hTyr-injected aSyn KO and WT mice at 6m post-AAV injection. *p < 0.05,
compared to respective contralateral (non-injected) side (two-way ANOVA; Student–Newman–Keuls post-hoc test). In all panels, values are mean ± SEM.
In b, n= 76 neurons from n= 4 mice (WT), n= 112 neurons from n= 4 mice (aSyn KO). In c, n= 3 (WT), n= 4 (aSyn KO) mice. In d (top), n= 9 (WT),
n= 5 (aSyn KO) mice. In d (bottom), n= 8 (WT), n= 6 (aSyn KO) mice. BF bright-field. In all panels, unstained NM appears as brown. Photomicrographs
correspond to 5-μm-thick sections
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formation of cytoplasmic inclusions. While in WT mice these
inclusions contained aSyn, p62, and ubiquitin, in aSyn-deficient
mice they were immunopositive for p62 and ubiquitin but lacked
aSyn (Fig. 7c and Supplementary Figure 6). Finally, to determine
whether aSyn actually contributed to NM-linked cell death in
NM-producing animals, we compared nigrostriatal degeneration
between AAV-hTyr-injected WT and aSyn-deficient mice. At 6 m
post-AAV-hTyr injections, WT and aSyn-deficient mice exhib-
ited comparable levels of striatal DA denervation and SNpc DA
neurodegeneration (Fig. 7d), indicating that aSyn is not con-
tributing to NM-linked cell death.
Overall, our results indicate that whereas NM accumulation
above a pathogenic threshold is associated with the formation of
PD-like aSyn-positive inclusions, aSyn is not actually required for
neither inclusion formation nor nigrostriatal neurodegeneration
in AAV-hTyr-injected animals.
General proteostasis failure in NM-producing cells. The accu-
mulation of p62-immunopositive inclusion bodies in NM-
producing rats and the dispensability of aSyn for their forma-
tion suggests a general failure of cellular proteostasis, beyond
aSyn, in NM-laden neurons. Indeed, p62-positive aggregates are
typically formed following inhibition of autophagy or
proteasome-mediated intracellular degradation51. Both autop-
hagy and ubiquitin-proteasome (UPS) systems are defective
within NM-laden, but not non-melanized, regions from post-
mortem PD brains52,53. In neural cells, suppression of basal
autophagy is sufficient to cause neurodegeneration, even in the
absence of any disease-associated mutant proteins54.
To determine whether NM accumulation may indeed affect
cellular proteostasis, additional experiments were performed in
differentiated human catecholaminergic neuroblastoma SH-SY5Y
cells inducible for hTyr expression. As in AAV-hTyr-injected
rats, induction of hTyr expression in these cells resulted in a
progressive intracellular production and accumulation of NM,
until most of the cellular cytoplasm was occupied by 6 days (d)
post-induction (Fig. 8a and Supplementary Figure 7). In humans,
intracellular NM is known to continuously accumulate over a
lifetime into autophagic structures23. In agreement with this, NM
from both NM-producing rats and hTyr-expressing cells
appeared enclosed within single-membrane-delimited mature
lysosomes/autophagolysosomes (Supplementary Figure 8) or
inside double-membrane-delimited autophagosomes (Fig. 8b),
as assessed by electron microscopy examination. Consistent with
the autophagic nature of NM granules, levels of the lysosomal
structural marker Lamp1 and the autophagosome marker LC3-II/
I increased in parallel with NM production in hTyr-expressing
cells (Fig. 8c and Supplementary Figure 7) and Lamp1 was shown
to co-localize with NM granules in AAV-hTyr-injected rodents
(Supplementary Figure 8). The continuous buildup of NM within
autophagic compartments was associated to a parallel decrease in
lysosomal-mediated proteolysis in hTyr-expressing cells, as
measured by intracellular protein degradation assay (Fig. 8d).
In addition to impaired lysosomal proteolysis, UPS activity was
also markedly reduced in NM-laden cells, as measured by
quantification of chymotrypsin-like activity of the 20 S protea-
some (Fig. 8e). Consistent with a failure in autophagy- and UPS-
mediated proteolysis, NM-laden cells exhibited a marked
accumulation of p62 protein by immunoblot (Fig. 8f and
Supplementary Figure 7). In addition, NM-laden cells also
exhibited extensive deposition of aSyn oligomers, as directly
visualized by aSyn proximity ligation assay (PLA) (Fig. 8g), a
method that has been previously used to detect aSyn oligomers in
post-mortem PD brains55. Impairment of both autophagy and
UPS is indicative of a general, late-stage proteostasis failure, in
which cell function and survival become compromised56. For
instance, mitochondrial quality control is tightly linked to the
proteolytic cytosolic systems and if the latter are blocked,
damaged mitochondria gradually accumulate57. Supporting this
concept, NM-laden cells exhibited impaired mitochondrial
respiration, as determined by respirometry with a Seahorse flux
analyzer system (Fig. 8h), and increased production of reactive
oxygen species (ROS), as assessed by flow cytometry with the
green fluorescent dye CellROX (Fig. 8i). Concomitantly, these
cells exhibited reduced metabolic activity, as revealed by a
decreased capacity to reduce resazurin to red-fluorescent
resorufin (Fig. 8j). These functional changes ultimately compro-
mised cell viability, as NM-producing cells started to die by 6d
post-hTyr induction (Fig. 8k). By that time, some NM-filled
neurons exhibited a nucleus that was apparently displaced and
extruded by NM while leaking their NM contents outside the cell
as they degenerate (Fig. 8l). By 8d, most NM-laden cells have
disappeared, with only some NM-filled cellular remains and
extracellular residual NM persisting in the medium (Fig. 8l).
These results indicate that the continuous buildup of NM
within autophagic compartments ultimately exhausts the autop-
hagic capacity of the cell, leading to a general failure of
proteostasis and subsequent dysfunction and degeneration of
NM-laden cells.
Modulation of NM levels and pathology in NM-producing rats.
To corroborate whether proteostasis failure was indeed respon-
sible for PD-like pathology linked to NM accumulation, we next
assessed the effects of enhancing proteostasis with transcription
factor EB (TFEB) in NM-producing rats. TFEB is a master reg-
ulator of autophagy that upon activation translocates into the
nucleus and induces the biogenesis of lysosomes and autopha-
gosomes, boosts autophagic cellular clearance, promotes lysoso-
mal exocytosis, and modulates general proteostasis58–62. By doing
so, TFEB overexpression has been shown to protect against
pathological substrate accumulation and cell death in several
rodent models of lysosomal storage disorders and neurodegen-
erative diseases63. To assess the effects of TFEB on NM-
producing rats, both AAV-TFEB and AAV-hTyr were co-
injected into the rat SNpc, with additional control groups of
animals receiving equivalent amounts of either vehicle, AAV-
hTyr or AAV-TFEB, separately. Co-injection of AAV-TFEB and
AAV-hTyr resulted in a marked nuclear expression of TFEB
within SNpc neurons, without interfering with hTyr expression or
NM production in these cells at 5 m post-AAV injection (Fig. 9a).
In agreement with the well-established role of TFEB at inducing
lysosomal biogenesis, SNpc DA neurons from AAV-TFEB-
injected animals exhibited increased levels of Lamp1, up to 1
year post-AAV injection (Fig. 9b). In hTyr-expressing cells, TFEB
overexpression was also confirmed to induce lysosomal exocytosis
(Supplementary Figure 8), as part of its known effects at pro-
moting cellular clearance60,62. In NM-producing rats, TFEB
overexpression markedly reduced inclusion body formation, both
in the nucleus (i.e. MB) and the cytosol (i.e. PB and LB-like) of
NM-laden neurons, compared to AAV-hTyr (only)-injected
animals (Fig. 9c). Remarkably, intracellular NM density was also
markedly reduced by TFEB within neurons displaying overtly
activated (i.e. nuclear) TFEB expression (Fig. 9d). TFEB-induced
reductions in intracellular NM and inclusion body formation
were associated, in turn, with a marked attenuation of NM-linked
neurodegenerative changes in hTyr/TFEB-expressing rats,
including attenuated loss of SNpc TH-positive cells, decreased
nigrostriatal denervation, reduced TH downregulation, and
diminished total SNpc DA neuronal death, all of which was
associated to a marked improvement of contralateral forepaw
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hypokinesia in these animals (Fig. 9e–i). Our results indicate that
NM-linked impaired proteostasis plays a pivotal role in the
initiation of PD-like pathology in AAV-hTyr-injected rats.
Discussion
In the present work, we have generated the first experimental
in vivo model of age-dependent production and intracellular
accumulation of human-like NM within PD-vulnerable SNpc DA
neurons, up to levels reached in elderly humans. While the aim of
generating such a model was to assess the consequences of pro-
gressive intracellular NM accumulation, our results may also shed
light on the actual mechanisms of NM synthesis in humans,
which are currently poorly understood. While it is generally
accepted that NM is formed by non-enzymatic DA autoxida-
tion41, in contrast to the well-known enzymatic synthesis of
peripheral melanins18, the striking resemblance between human
NM and NM from AAV-hTyr-injected rats raises the question of
a potential enzymatic contribution to NM synthesis, either by
tyrosinase itself, which is present at low levels in human SNpc, or
by alternative tyrosinase-related enzymes. Further supporting a
potential enzymatic involvement in NM synthesis, it has been
reported that increased levels of DA and oxidized DA in mice and
rats, either with chronic L-DOPA treatment44,64 or TH over-
expression45, is apparently not sufficient by itself to produce NM
in these animals, as might be expected if NM represents a mere
process of autoxidized DA. In contrast, in the present study,
conspicuous NM production was obtained solely by over-
expressing hTyr in the rodent brain. In addition, our observation
of tyrosinase expression being normally present at low levels in
the human brain further supports the possibility of a potential
enzymatic contribution to NM synthesis. The latter results concur
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and after (ON) treatment with doxycycline. Bottom, quantification of intracellular NM optical density post-hTyr induction. *p < 0.05, compared to OFF and
ON 1d (ANOVA on ranks; Dunn’s post-hoc test). Scale bar, 12.5 μm. b Electron micrographs of NM granules in hTyr-expressing cells (6d post-hTyr
induction). Arrowhead, double-membrane; asterisk, lipid droplet. Scale bar, 0.5 μm. c Immunoblot levels of Lamp1 (left) and LC3 (right) post-hTyr
induction. d Lysosomal proteolysis post-hTyr induction. e Ubiquitin-proteasome (UPS) activity post-hTyr induction. f Immunoblot levels of p62 post-hTyr
induction. g Representative images (left) and quantification (right) of aSyn oligomers (red) in hTyr-expressing cells as detected by aSyn-proximity ligation
assay. Hoechst, nuclei (blue). BF bright-field. Scale bar, 25 μm. h Mitochondrial oxygen consumption rate (OCR) post-hTyr induction. i ROS production
post-hTyr induction. MFI mean fluorescence intensity. j Cellular metabolic activity post-hTyr induction. k Number of surviving cells post-hTyr induction.
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to β-actin expression levels. BF bright-field, KDa kilodaltons. Unstained NM appears as brown. In c–f, h, j, *p < 0.05, compared to OFF (one-way ANOVA;
Student–Newman–Keuls post-hoc test). In g, *p < 0.05, compared to OFF; #p < 0.05, compared to ON 3d (ANOVA on ranks; Dunn’s post-hoc test). In i,
*p < 0.05, compared to OFF; #p < 0.05, compared to ON 3d (one-way ANOVA; Student–Newman–Keuls post-hoc test). In k, *p < 0.05, compared to
OFF (ANOVA on ranks; Dunn’s post-hoc test)
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with previous reports having detected the presence of brain tyr-
osinase in humans at the level of mRNA, protein, and enzymatic
activity20–22, as well as with results from three different micro-
array experiments in human brain tissue (Entrez_id: 7299; Allen
Brain Institute), non-human primate brain tissue (Entrez_id:
705792; NIH Blueprint NHP Atlas), and developing human
prenatal brain tissue (Entrez_id: 7299, BrainSpan Atlas of the
developing human brain) consistently detecting the presence of
tyrosinase transcripts at low levels. In rodents, tyrosinase
expression has been previously detected in mouse SN by in situ
hybridization (Allen Brain Atlas data portal) and qPCR65.
However, other studies have failed to detect tyrosinase expression
in the human brain66,67. The apparently conflicting results
regarding the presence or absence of tyrosinase in the human
brain may be attributed to the low levels at which tyrosinase may
be actually expressed in the brain and thus the requirement of
adequate methodological approaches for its detection. For
instance, brain tyrosinase has not been detected in humans
when using immunohistochemistry or western blot (WB) from
total protein homogenates66,67, two techniques unable to detect
such low levels of protein expression at which tyrosinase may
be present in the brain. In contrast, tyrosinase expression
has been systematically detected in the human brain when
using either RT-PCR/qPCR, in situ hybridization or WB with
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tyrosinase-immunoprecipitated protein samples20–22 (see also
Supplementary Figure 1). Further studies are required to deter-
mine in a definite manner a potential contribution of tyrosinase
or other enzymes in NM synthesis.
The functional significance of NM production remains spec-
ulative. Until recently, NM was considered merely as a waste
product of cellular metabolism that was devoid of any physiolo-
gical function. However, increasing evidence indicates that NM
can interact with the cellular environment and influence cell
function and survival. For instance, similar to peripheral mela-
nins, NM possesses antioxidant and free radical scavenging
properties, which might be important for catecholaminergic
neurons, as these cells endure a particularly high oxidative bur-
den68. In this context, it has been proposed that the synthesis of
NM may represent an antioxidant mechanism to remove exces-
sive cytosolic DA-derived quinones and semiquinones, thereby
blocking their potential toxicity68. Supporting this concept, hTyr-
induced oxidized DA species did not significantly increase in
hTyr-injected rats, suggesting that the continuous conversion of
these species into NM may be preventing their potentially toxic
accumulation in these animals. Moreover, NM is able to bind and
sequester potentially toxic metals, in particular redox-active ferric
ions, as well as environmental parkinsonian toxins, such as 1-
methyl-4-phenylpyridinium (MPP+, the active metabolite of
MPTP) or the pesticide paraquat69. Despite a putative beneficial
role of NM synthesis, our results suggest that the progressive
buildup of intracellular NM may ultimately interfere with normal
cell function and trigger PD-like neuronal dysfunction/degen-
eration when reaching a pathogenic threshold of accumulation,
regardless of whether the initial synthesis of NM is a protective or
inert process.
Neuronal dysfunction/degeneration in NM-producing AAV-
hTyr-injected rats could potentially result from DA-mediated
neurotoxicity by increased hTyr-mediated production of poten-
tially toxic oxidized DA species. However, as discussed above, the
continuous formation of NM in AAV-hTyr-injected rats seems to
prevent the significant accumulation of oxidized DA species in
these animals. Further arguing against a major pathogenic role for
oxidized DA species in AAV-hTyr-injected rodents, it has been
recently reported by two independent groups44,45 that DA-
mediated toxicity in rodents: (i) is only observed in animals
displaying additional PD-related alterations, such as DJ-1 defi-
ciency44 or overexpression of PD-linked A53T mutant aSyn45,
but not in regular WT animals44,45, in contrast to our results in
AAV-hTyr-injected WT rodents; (ii) is dependent on aSyn44,45,
in contrast to the dispensability of aSyn that we reported for
AAV-hTyr-mediated toxicity. In this context, the continuous
accumulation of NM over a lifetime into undegraded or partly
degraded autophagic structures, either in an attempt by the cell to
degrade this pigment or to isolate it from the rest of the cell to
prevent its potential pathological interaction with cytosolic cel-
lular components, may ultimately exhaust the vesicular storage
capacity of the cell, interfere with lysosomal proteases and other
degradative pathways, impair intracellular vesicular trafficking
and alter endocytic/secretory tasks17,23. Consistent with such a
scenario, here we found that NM accumulation was associated to
a general impairment of cellular proteostasis accompanied by the
formation of PD-like intracellular inclusions, neuronal dysfunc-
tion, and neurodegeneration. Supporting a pivotal detrimental
role for impaired proteostasis in NM-laden cells, enhancement of
lysosomal-mediated proteolysis by TFEB overexpression in NM-
producing rats reduced intracellular NM density, attenuated PD-
like inclusion formation, prevented nigrostriatal neurodegenera-
tion, and reversed motor impairment.
The results presented here could explain the major pathologic
features of PD, including: (i) the selective vulnerability of specific
neuronal groups (i.e. those containing NM); (ii) the correlation of
PD with age (as NM accumulates with age); (iii) the reported
cellular alterations linked to PD, such as mitochondrial dys-
function, increased ROS production, autophagy/UPS defects,
inclusion body formation, and neuroinflammation, all of which
have been proposed as potential primary pathogenic events in PD
but, in light of our results, may in fact occur concomitantly
secondarily to intracellular MN accumulation; (iv) the uniqueness
of PD to humans, since only humans accumulate such high levels
of intracellular NM16. However, while NM is present in the brain
of all humans, only some individuals actually develop PD (1 to up
~5% of the population over 60, increasing with age)70. Based on
our findings, PD will appear in those subjects that have reached
earlier the pathogenic threshold of intracellular NM accumula-
tion. Supporting this concept, we found that intracellular NM
levels appear indeed above this pathogenic threshold in the brains
of PD patients and pre-symptomatic PD subjects (i.e. ILBD) while
in the brains of elderly, aged-matched healthy individuals intra-
cellular NM levels were maintained below this pathogenic
threshold. In PD patients, the intracellular buildup of NM might
be accelerated, thereby reaching earlier the pathogenic threshold
of intracellular NM accumulation. This could occur, for instance:
Fig. 9 Therapeutic enhancement of lysosomal proteostasis in NM-producing rats. a Ipsilateral SNpc sections from rats co-injected with AAV-hTyr/flagged-
AAV-TFEB immunostained with Flag (blue, left) or hTyr (blue, right) at 5 m post-AAV. NM, brown. Arrowheads, nuclear Flag/TFEB. Scale bar, 25 μm.
b Lamp1 immunolabeling (blue) in ipsilateral SNpc of AAV-TFEB-injected rats (12 m post-AAV). *p < 0.05, compared to contralateral (non-injected) SNpc
(Mann–Whitney rank sum test). Scale bar, 12.5 μm. c NM-laden neurons with p62-positive MB (left) and PB/LB-like inclusions (right) in ipsilateral SNpc
from AAV-hTyr- and AAV-hTyr/TFEB-injected rats (2 m post-AAV). *p < 0.05, compared to AAV-hTyr-injected animals (left, Mann–Whitney rank sum
test; right, two-way ANOVA, Student–Newman–Keuls post-hoc test). d Intracellular NM density in ipsilateral SNpc TH-positive neurons from rats co-
injected with AAV-TFEB/AAV-hTyr (12 m post-AAV). White arrowhead, Flag/TFEB-positive nucleus; black arrowhead, Flag/TFEB-negative nucleus.
Scale bar, 12.5 μm. *p < 0.05, compared to Flag/TFEB-negative neurons (Mann–Whitney rank sum test). e SNpc TH-positive neurons at 12m post-AAV/
vehicle injections. f Striatal TH-positive fibers at 12m post-AAV/vehicle injections. In e, f, *p < 0.05, compared to respective contralateral side; #p < 0.05,
compared to ipsilateral vehicle- and AAV-TFEB-injected animals; §p < 0.05, compared to ipsilateral AAV-hTyr-injected animals (two-way ANOVA;
Student–Newman–Keuls post-hoc test). g TH downregulation within NM-laden neurons (12 m post-AAV). *p < 0.05, compared to AAV-hTyr-injected
animals (two-tailed t-test). h Total SNpc DA neurons at 12 m post-AAV/vehicle injections. *p < 0.05, compared to respective contralateral side; #p < 0.05,
compared to ipsilateral vehicle- and AAV-TFEB-injected animals (two-way ANOVA; Student–Newman–Keuls post-hoc test). i Contralateral forepaw use in
AAV-hTyr- and AAV-hTyr/TFEB-injected rats (12 m post-AAV). *p < 0.05, compared to AAV-hTyr (only)-injected animals (two-tailed t-test). Dashed line
indicates average contralateral forepaw use in control-injected rats. In all panels, values are mean ± SEM. In b, n= 138 neurons from n= 4 non-injected rats
and n= 203 neurons from n= 5 AAV-TFEB-injected rats. In c, n= 6 (hTyr), n= 8 (hTyr+ TFEB) rats. In d, n= 132 nuclear flag- neurons and n= 173
nuclear flag+ neurons from n= 4 AAV-hTyr+ TFEB-injected rats. In e and h, n= 7 (vehicle), n= 4 (TFEB), n= 5 (hTyr), n= 4 (hTyr+ TFEB) rats. In f,
n= 7 (vehicle), n= 6 (TFEB), n= 4 (hTyr), n= 3 (hTyr+ TFEB) rats. In g, n= 4 animals per group. In i, n= 12 (control), n= 3 (hTyr), n= 4 (hTyr+ TFEB)
rats. BF bright-field. Photomicrographs correspond to 5-μm-thick sections
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(i) by an abnormal upregulation/increased activity of hTyr or
other putative NM-producing enzymes, such as tyrosinase-related
protein 2 (i.e. dopachrome tautomerase), the expression of which
we found significantly increased in induced pluripotent stem cell
(iPSC)-derived DA neurons from PD patients;71 or (ii) by
increased cytosolic DA levels, which may convert to NM, as a
consequence of defects in VMAT2-dependent DA encapsulation
within synaptic vesicles, as it has been shown in early PD cases26.
Based on our results, strategies to maintain or decrease intra-
cellular NM levels below their pathogenic threshold may provide
unprecedented therapeutic opportunities to prevent, halt, or delay
neuronal dysfunction and degeneration linked to PD. Given the
putative protective role of NM synthesis (see above), therapeutic
strategies aimed at maintaining or decreasing intracellular NM
levels below their pathogenic threshold should be preferentially
targeted at preventing NM accumulation once NM has already
been produced, for instance by promoting its elimination as
reported here with TFEB. In contrast, the inhibition of NM
synthesis itself may prove instead detrimental. For instance, a rare
loss-of-function mutation in hTyr linked to albinism has been
recently associated to an increased risk for PD72, which has been
attributed to the possible inability of this hTyr variant to syn-
thesize NM and the subsequent accumulation of potentially toxic
DA-derived species that cannot be detoxified by its conversion
into NM. In this context, it would be very important for any
therapeutic strategy aimed at modulating NM levels to tightly
regulate NM levels above its protective threshold and below its
pathogenic threshold revealed here.
Overall, with the introduction into experimental in vivo
research of a factor so intimately linked to PD such as NM, which
has been so-far neglected in PD animal modeling, the results
presented here may open new research avenues and lead to a
paradigm shift in the field of PD and, in a broader sense, brain
aging.
Methods
Animals. Adult male Sprague–Dawley rats (Charles River), 225–250 g at the time
of surgery, were housed two to three per cage with ad libitum access to food and
water during a 12 h (h) light/dark cycle. All the experimental and surgical proce-
dures were conducted in strict accordance with the European (Directive 2010/63/
UE) and Spanish laws and regulations (Real Decreto 53/2013; Generalitat de
Catalunya Decret 214/97) on the protection of animals used for experimental and
other scientific purposes, and approved by the Vall d’Hebron Research Institute
(VHIR) Ethical Experimentation Committee. Rats were randomly distributed
into the different experimental groups and control and experimental groups were
processed at once to minimize bias. When appropriate, additional sporadic
experiments were performed in aSyn-deficient73 and wild-type C57BL/6 mice,
as indicated.
Viral vector production. Recombinant AAV vector serotype 2/1 expressing the
human tyrosinase cDNA driven by the CMV promoter (AAV-hTyr) and the
corresponding control empty vector (AAV-EV) were produced at the Viral Vector
Production Unit of the Autonomous University of Barcelona (UPV-UAB, Spain).
Briefly, rAAV vectors were produced by triple transfection of 2 × 108 HEK293 cells
with 250 µg of pAAV, 250 µg of pRepCap, and 500 µg of pXX6 plasmid mixed with
polyethylenimine (PEI; branched, MW 25,000; Sigma-Aldrich). The UPV-UAB
generated a pAAV plasmid containing the ITRs of the AAV2 genome, a multi-
cloning site to facilitate cloning of expression cassettes, and ampicillin resistance
gene for selection. 48 h after transfection, cells were harvested by centrifugation
(200 × g, 10 min); resuspended in 30 ml of 20 mM NaCl, 2 mM MgCl2, and 50 mM
Tris-HCl (pH 8.5), and lysed by three freeze–thaw cycles. Cell lysate was clarified
by centrifugation (2000 × g, 10 min) and the rAAV particles were purified from the
supernatant by iodixanol gradient as previously described (Zolotukhin et al., 1999
Gene Therapy). The clarified lysate was treated with 50 U/ml of Benzonase
(Novagen; 1 h, 37 °C) and centrifuged (3000 × g, 20 min). The vector-containing
supernatant was collected and adjusted to 200 mM NaCl using a 5-M stock
solution. To precipitate the virus from the clarified cell lysate, polyethylene glycol
(PEG8000; Sigma-Aldrich) was added to a final concentration of 8% and the
mixture was incubated (3 h, 4 °C) and centrifuged (8000 × g, 15 min). The AAV-
containing pellets were resuspended in 20 mM NaCl, 2 mM MgCl2, and 50 mM
Tris-HCl (pH 8.5) and incubated for 48 h at 4 °C. The rAAV titration method used
was based on the quantitation of encapsidated DNA with the fluorescent dye
PicoGreen® as previously described74, and the following vector concentrations
were obtained: AAV-hTyr: 1.7 × 1013 gc/mL (batch a), 2.43 × 1012 gc/mL (batch b);
AAV-EV: 2.48 × 1013 gc/mL.
AAV serotype 2/9 containing the murine Tfeb cDNA fused to 3 Flag epitopes
under control of the cytomegalovirus (CMV) promoter (AAV-TFEB;
concentration: 3 × 1012 gc/mL) was provided by TIGEM AAV Vector Core Facility
(Italy)59.
Surgical procedures. All surgical procedures on rodents were performed with the
animals placed in a stereotaxic frame under general anesthesia using isofluorane
(5% for the induction phase and 2% for the maintenance phase) (Baxter). Vector
solutions were injected using a 10 μL Hamilton syringe fitted with a glass capillary
(Hamilton model Cat#701). Animals received 2 μL (rats) or 1 μl (mice) of either
AAV-hTyr, AAV-EV, vehicle or, in the experiments involving TFEB, a 1:1 mixture
of AAV-hTyr/AAV-TFEB, AAV-hTyr/vehicle, or AAV-TFEB/vehicle. In both
rats and mice, infusion was performed at a rate of 0.4 μL/min and the needle was
left in place for an additional 4 min period before it was slowly retracted. Injection
was carried out unilaterally on the right side of the brain at the following coor-
dinates (flat skull position), right above the substantia nigra pars compacta (SNpc):
antero-posterior: −5.2 mm (rats), −2.9 mm (mice); medio-lateral: −2 mm (rats),
−1.3 mm (mice); dorso-ventral: −7.6 mm (rats), −4.2 mm (mice) below dural
surface, calculated relative to bregma according to the stereotaxic atlas of Paxinos
and Watson75.
Transduction efficiency. AAV-hTyr transduction efficiency was determined at
2–4 weeks post-AAV injection (n= 6–8 rats) either by: (i) assessing hTyr
expression within SNpc tyrosine hydroxylase (TH)-positive cells by double
immunofluorescence with antibodies against TH and hTyr in six coronal midbrain
sections through the entire SNpc, using the Cell Counter plugin on ImageJ software
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland,
USA, 1997-2016); (ii) by counting the number of NM-positive neurons versus the
total number of SNpc TH-positive neurons, as described below.
Brain processing for histological analyses. Animals were deeply anesthetized
with sodium pentobarbital (50 mg/kg, i.p.) and then perfused through the left
ventricle with saline [0.9% (wt/vol)] at room temperature (RT), followed by
ice-cold formaldehyde solution 4% phosphate buffered for histology (Panreac). The
brains were removed and post-fixed for 24 h in the same fixative and subsequently
processed for paraffin embedding following standard procedures or cryoprotected
for 24–48 h in 30% sucrose at 4 °C and frozen. Sectioning was performed with a
sliding microtome (Leica, Germany) at 5-µm-thickness for paraffin samples or
in a cryostat at 20- or 30-µm-thickness for frozen samples (Leica, Germany).
Immunohistochemistry. Deparaffinized rodent brain sections were quenched for
10 min in 3% H2O2-10% (vol/vol) methanol. Antigen retrieval in paraffin sections
was performed with a 10-mM citric acid solution at pH 6.0 in a microwave for
20 min. Sections were rinsed 3 times in 0.1 M Tris buffered saline (TBS) between
each incubation period. Blocking for 1 h with 5% (vol/vol) normal goat serum
(NGS, Vector Laboratories) was followed by incubation with the appropriate pri-
mary antibody at 4 °C for 48 h in 2% (vol/vol) serum and with the corresponding
biotinylated antibody (Vector Laboratories). Sections were visualized by incubation
with avidin–biotin–peroxidase complex (Ultrasensitive and Immunopure ABC
Peroxidase staining kits for the striatum and for the SNpc, respectively; Thermo
Fisher Scientific), using the VectorSG Peroxidase Substrate Kit (Vector Labora-
tories) as a chromogen, and then mounted and coverslipped with DPX mounting
medium (Sigma-Aldrich). Bright-field section images were examined using: (i)
Zeiss AX10 LabA1 microscope coupled to an AxioCam ERc5s camera; (ii) Zeiss
Imager.D1 microscope coupled to an AxioCam MRc camera; (iii) Zeiss Stemi 2000-
C magnifying glass coupled to an AxioCam ERc5s camera. Images were processed
with ZEN 2011 software (Zeiss, Germany). For immunofluorescence, a similar
protocol was used without the quenching step. Preincubation was performed with
5% (vol/vol) NGS and 0.1% (vol/vol) Triton X-100 (Sigma-Aldrich) in phosphate
buffered saline (PBS) solution. Corresponding primary antibodies were incubated
together overnight at 4 °C in 2% (vol/vol) serum and adequate Alexa 488, 594,
and 647-conjugated secondary antibodies (1:1000, Thermo Fisher Scientific) were
incubated simultaneously for 1 h at RT in 2% (vol/vol) serum. Nuclei were stained
with Hoechst 33342 (1:2000, Thermo Fisher Scientific) in 1× PBS for 10 min.
Sections were coverslipped using the DakoCytomation Fluorescent Mounting
Medium (Dako). Immunofluorescence section images were examined using: (i) an
Olympus FSX100 microscope with a DP72 incorporated camera and processed
with the FSX-BSW software (Olympus, Germany), and in an Olympus BX61
microscope with a DP72 camera and processed with the Cell Sens Entry
v1.8 software (Olympus, Germany).
Primary antibodies and dilution factors were as follows: mouse anti-DAT
(1:500, Novus Biologicals, Cat#NBP2-22164); guinea pig anti-VMAT2 (1:5000,
Progen, Cat#16085); rabbit anti-TH (1:40000 for SNpc and 1:3500 for striatum
immunohistochemistry in paraffin sections; 1:2000 for SNpc and 1:5000 for
striatum immunohistochemistry in free-floating sections; 1:1000 for
immunofluorescence, Calbiochem, Cat#657012); mouse anti-TH (1:1000, Merck
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Millipore, Cat#MAB5280); mouse anti-tyrosinase (1:500, Thermo Fisher Scientific,
Cat#MS-800-P1); mouse anti-FLAG (1:1000, Sigma-Aldrich, Cat#F3165); rabbit
anti-GAD65+GAD67 (1:750, Abcam, Cat#ab49832); mouse anti-GFAP (1:1000,
Sigma-Aldrich, Cat#G3893); rabbit anti-Iba1 (1:1000, Wako, Cat#019-19741);
mouse anti-CD68 (1:100, Serotec, Cat#MCA341R); DyLight 594 Lectin (1:500,
Vector Laboratories, Cat#DL-1177); guinea pig anti-p62 (1:1000, Progen,
Cat#GP62-C); rabbit anti-Ubiquitin (1:500, Dako, Cat#Z0458); mouse anti-aSyn
(1:1000, BD Biosciences, Cat#610786); mouse anti phosphorylated(Ser129)-aSyn
(1:1000, Wako, Cat#015-25191); rabbit anti-Lamp1 (1:250, GeneTex,
Cat#GTX19294); rat anti-Lamp1 (1:4000, Santa Cruz, Cat#sc-19992).
Masson-Fontana and hematoxylin-eosin stainings. Staining of NM granules in
5-µm-thick paraffin-embedded rat brain sections was performed using the Masson-
Fontana Staining Kit (DiaPath); this procedure is based on the ability of NM to
chelate metals by reducing silver nitrate to a visible metallic state. Briefly, paraffin
tissue sections were dewaxed and rehydrated by heating at 60 °C for 10 min,
followed by xylene (5 min, 3 times) and ethanol serial washes (100-95-70%-H2O,
5 min each). Staining was performed by incubating the sections with ammoniac
solution for 40 min at 56 °C, followed by sodium thiosulphate for 2 min and a final
counterstain with Kernechtrot for 7 min. Between each step, samples were rinsed in
distilled water. Standard hematoxylin-eosin (H&E) staining was performed in 5-
µm-thick paraffin-embedded SNpc section for each animal. In these sections, SNpc
DA neurons were identified by the visualization of unstained NM pigment.
Magnetic resonance imaging. 1H-Magnetic resonance imaging (MRI) studies in
rats were performed in a 7T Bruker BioSpec 70/30 USR (Bruker BioSpin GmbH,
Karlsruhe, Germany) equipped with a mini-imaging gradient set (400 mT/m), a
linearly polarized transmit volume coil (72 mm inner diameter) and a dedicated
brain surface coil as receiver. All MRI data were acquired and processed on a Linux
computer using Paravision 5.1 software (Bruker BioSpin GmbH, Karlsruhe, Ger-
many). Fixed rat brains were placed in a 15-ml Falcon tube and embedded in 2%
agarose to diminish susceptibility artefacts. Low-resolution T2-weighted fast spin-
echo images were initially obtained in axial, sagittal, and coronal planes to be used
as reference scout images. Imaging parameters for these images were: effective echo
time (TEeff)= 36 ms; repetition time (TR)= 3 s; echo train length (ETL)= 8; field
of view (FOV)= 6 × 6 cm2; matrix size (MTX)= 128 × 128; slice thickness (ST)=
2 mm; gap between slices (gap)= 0.5 mm; number of slices (NS)= 25 -axial,
10-sagittal, 11 -coronal; number of averages (NA)= 1. High-resolution T1-
weighted spin-echo images were acquired afterwards in the axial and coronal
planes containing the region of interest with the following parameters: TE= 9 ms;
TR= 500 ms; NA= 128; NS= 20 (axial) and 7 (coronal); FOV= 1.92 × 1.92 cm2;
MTX= 128 × 128 (axial) and 192 × 128 (coronal); ST= 0.25 mm (axial) and 0.35
(coronal); thus resulting in a spatial resolution of 150 × 150 × 250 µm3 (axial)
and 100 × 150 × 350 µm3 (coronal). The acquisition time was 2 h and 16 min for
each high-resolution image.
Intracellular NM quantifications. An average of 165 neurons (94 in mice) were
analyzed at each time-point post-AAV-hTyr injection, i.e. 0.5, 1, 2, 4, 12, and
24 months (m), corresponding to 5–7 different animals per time-point. For the
experiments related to TFEB, an average of 108 neurons were analyzed at 12 m
post-AAV injections, corresponding to 3–4 different animals per experimental
group. In all cases, a representative 5-µm-thick paraffin-embedded H&E-stained
rat midbrain section was selected for each animal. In each section, all NM-positive
neurons were examined at an objective magnification of ×63. Images covering all
the SNpc region were taken with a Zeiss Imager. D1 microscope was coupled to an
Axiocam MRc camera. Quantification of the intracellular density of NM pigment
was achieved by means of optical densitometry using ImageJ software (NIH, USA).
The pixel brightness values for all individual NM-positive cells (excluding the
nucleus) in all acquired images were measured and corrected for non-specific
background staining by subtracting values obtained from the neuropil in the same
images. In animals co-injected with AAV-hTyr and AAV-TFEB, additional
quantifications of intracellular NM density were performed as above in bright-field
photomicrographs at ×63 magnification, taking into account whether NM-laden
cells exhibited flagged TFEB-positive or TFEB-negative nuclei. All quantifications
were performed by an investigator blinded to the experimental groups. For NM
quantifications in post-mortem human samples and cultured cells, see details
below. Of note, because intracellular NM density in both humans and rodents was
measured as the intensity of the NM signal normalized to the respective neuronal
surface (excluding the nucleus), these values can be compared between species.
Stereological cell counting. Assessment of the total number of SNpc TH-positive
neurons, the number of SNpc NM-laden neurons and the total number of DA
neurons in the SNpc was performed according to the fractionator principle, using
the MBF Bioscience StereoInvestigator 11 (64 bits) Software (Micro Brightfield).
Serial 5-µm-thick paraffin-embedded sections covering the entire SNpc were
included in the counting procedure (every 17th section in rats and every sixth
section in mice, for a total of 6–8 sections analyzed/animal). The following sam-
pling parameters were used: (i) a fixed counting frame with a width and length of
50 μm; (ii) a sampling grid size of 100 × 75 μm in rats and of 125 × 100 μm in mice.
The counting frames were placed randomly by the software at the intersections of
the grid within the outlined structure of interest. The cells in one brain side, contra-
or ipsilateral to the injection site, were counted following the unbiased sampling
rule using a ×100 lens and included in the measurement when they came into focus
within the dissector. A coefficient of error of <0.10 was accepted. Data for the total
numbers of TH-positive neurons and NM-containing neurons in the SNpc are
expressed as the absolute numbers in the non-injected contralateral side and in
the AAV-injected ipsilateral side. The total number of SNpc DA neurons was
calculated by considering all TH+NM+, TH−NM+, and TH+NM− neurons. The
percentage of TH down-regulation was calculated by considering the total number
of TH+NM+ and the total number of TH−NM+ with respect to the total number
of neurons containing NM in the different experimental groups. AAV-hTyr-
injected rats were analyzed at different time-points after injection: 0.5 m (n= 8),
1 m (n= 7), 2 m (n= 5), 4 m (n= 8), 12 m (n= 7), and 24 m (n= 6). AAV-hTyr
(n= 5), AAV-TFEB (n= 4), AAV-hTyr+ TFEB (n= 4), and vehicle-injected rats
(n= 7) were analyzed at 12 m post-injection. AAV-EV-injected rats were analyzed
at 4 m (n= 7), 12 m (n= 4), and 24 m (n= 3) post-injection. Vehicle-injected
rats were analyzed at 4 and 12 m post-surgery (n= 8 animals/group). AAV-hTyr-
injected mice were analyzed at 6 m post-AAV injections: WT (n= 8), aSyn KO
(n= 6). All quantifications were performed by an investigator blinded to the
experimental groups.
Quantification of neuropathological parameters. The absolute number of
extracellular NM aggregates was estimated within the same sections in which SNpc
TH-positive stereological cell counts were performed (i.e. serial 5-µm-thick
paraffin-embedded sections covering the entire SNpc, taking every 17th section
in rats and every 6th section in mice, for a total of 6–8 sections analyzed/animal).
The number of neuronophagic events were assessed in serial H&E-stained 5-µm-
thick paraffin-embedded sections covering the entire SNpc. The number of p62-
immunopositive Marinesco bodies, PB, and Lewy body-like inclusions was counted
from SNpc sections fluorescently immunostained with guinea pig anti-p62 (1:1000,
Progen), rabbit anti-ubiquitin (1:500, Dako), and mouse anti-aSyn (1:1000, BD
Biosciences). The total number of p62-positive inclusions falling into each category
was counted from images covering the whole SNpc region in each section.
Quantifications were performed in AAV-hTyr-injected at different time-points
post-AAV-hTyr injection: 0.5 m (n= 8), 1 m (n= 5), 2 m (n= 6), 4 m (n= 5),
12 m (n= 6), and 24 m (n= 5). AAV-hTyr-injected mice were analyzed at 2 m
post-AAV injections: WT (n= 3), aSyn KO (n= 4). AAV-hTyr (n= 5), AAV-
TFEB (n= 4), AAV-hTyr+ TFEB (n= 4), and vehicle-injected rats (n= 7) were
analyzed at 12 m post-injection. All quantifications were performed by an inves-
tigator blinded to the experimental groups.
Optical densitometry analyses. The density of TH-positive fibers in the striatum
was measured by densitometry in serial coronal sections covering the whole region
(10 sections/animal). TH-immunostained 5-µm-thick paraffin-embedded sections
were scanned with an Epson Perfection v750 Pro scanner and the resulting images
were quantified using Sigma Scan Pro 5 software (Systat Software Inc, USA).
Striatal densitometry values were corrected for non-specific background staining by
subtracting densitometric values obtained from the cortex. Data are expressed as
the percentage of the densitometric value of the equivalent anatomical area from
the non-injected contralateral side of the same animal. For the AAV-hTyr groups,
animals were analyzed at different time-points after AAV-hTyr injection: 0.5 m
(n= 8), 1 m (n= 7), 2 m (n= 5), 4 m (n= 8), 12 m (n= 7), and 24 m (n= 6). For
the AAV-hTyr/TFEB-related experiments, animals were analyzed at 12 m post-
injection: AAV-hTyr (n= 4), AAV-TFEB (n= 6), AAV-hTyr+ TFEB (n= 3), and
vehicle-injected rats (n= 7). For control experiments, animals were analyzed at
different time-points after injection: AAV-EV-injected rats at 4 m (n= 7), 12 m
(n= 4), and 24 m (n= 3); vehicle-injected rats at 4 and 12 m (n= 8 animals
per group). AAV-hTyr-injected mice were analyzed at 6 m post-AAV injections:
WT (n= 9), aSyn KO (n= 5). All quantifications were performed by an investi-
gator blinded to the experimental groups.
The density of GAD65+GAD67-positive fibers in the superior colliculus was
measured by densitometry in selected coronal sections around Bregma −5.64 mm.
GAD65+GAD67-immunostained 5-µm-thick paraffin-embedded sections were
scanned as previously described and densitometry values were corrected for non-
specific background staining by subtracting densitometric values obtained from the
adjacent ventral parenquima. Data are expressed as the percentage of the
densitometric value of the equivalent anatomical area from the non-injected
contralateral side of the same animal. Animals were analyzed at different time-
points: (i) naive rats: 4 m (n= 4) and 12 m (n= 5); (ii) vehicle-injected rats: 4 m
(n= 6) and 12 m (n= 5); (iii) AAV-EV-injected rats: 12–24 m (n= 4); (iv) AAV-
hTyr-injected rats: 4 m (n= 3) and 12–24 m (n= 7).
Lamp1 protein expression levels in SNpc neurons from AAV-TFEB-injected
rats (n= 5 animals) were measured by intracellular optical densitometry using
ImageJ software. Five-µm-thick paraffin-embedded SNpc sections were
immunostained for Lamp1 and 200 cells were randomly selected for analysis in the
AAV-TFEB-injected ipsilateral side and the non-injected contralateral side of the
same animal. All quantifications were performed by an investigator blinded to
the experimental groups.
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Cylinder behavioral test. Rats were tested for left and right forepaw use with the
cylinder test 1 week before surgery (to establish the basal conditions for each
animal) and at different times post-AAV-hTyr injection thereafter (0.5, 1, 2, 3, 6,
12, and 24 m). Rats that presented an asymmetric usage of the right-left forepaws
at basal examination were excluded from the analysis. At the beginning of the
experiment, the number of animals for each condition was: n= 29 (AAV-hTyr-
injected rats) and n= 20 (AAV-EV-injected rats). Because a randomly selected
group of animals was euthanized for histological analyses at each time-point fol-
lowing the cylinder test, at the end of the behavioral analysis (24 m): n= 6 (AAV-
hTyr-injected rats) and n= 4 (AAV-EEV-injected rats) animals remained. For the
experiments with TFEB, vehicle (n= 7), AAV-TFEB (n= 5), AAV-hTyr (n= 3),
and AAV-hTyr+ TFEB (n= 4) injected rats were analyzed 1 week before surgery
(to establish the basal conditions for each animal) and then every 4 weeks until rats
were killed 12 m post-injection. For the performance of the cylinder test, rats were
first allowed to habituate to the experimental room for at least 1 h before each test.
Then, rats were put in a glass cylinder and the total number of left and right
forepaw touches performed within 5 min was counted. Data are presented as the
percentage of the contralateral paw usage with respect to either AAV-EV-injected
or control (vehicle and AAV-TFEB-injected) rats, as appropriate. Behavioral
equipment was cleaned with 70% ethanol after each test session to avoid olfactory
cues. All behavioral tests were performed during the light cycle by an investigator
blinded to the experimental groups.
In vivo microdialysis. To assess local effects of D-amphetamine sulfate and
veratridine on striatal DA release in microdialysis experiments, drugs were
dissolved in artificial cerebrospinal fluid (aCSF: 125 mM NaCl, 2.5 mM KCl,
1.26 mM CaCl2, and 1.18 mM MgCl2) and administered by reverse dialysis at
the stated concentrations (uncorrected for membrane recovery). Stock solutions
of veratridine were made in dimethyl sulfoxide and were diluted to appropriate
concentrations in aCSF to reach 1% dimethyl sulfoxide. Concentrated solutions
(1 mM; pH adjusted to 6.5–7 with NaHCO3 when necessary) were stored at
−80 °C and working solutions were prepared daily by dilution in aCSF.
Microdialysis procedures in vehicle- (n= 6) and AAV-hTyr-injected rats (n= 6
for the Amphetamine experiment and n= 8 for the Veratridine experiment)
were conducted essentially as described previously76. Rats were anaesthetized
with sodium pentobarbital (60 mg/kg, i.p.) and implanted with 3-mm concentric
dialysis probes (Cuprophan membrane, 6000 Da molecular weight cut-off) in
the ipsilateral striatum at the following coordinates (in mm): AP,+ 0.5; L, −3.0
and DV, 6.6 (ref. 75). Microdialysis experiments were performed in freely moving
rats 24–48 h after surgery, except in experiments involving the electrical
stimulation of the medial forebrain bundle (MFB) (see below). Probes were
perfused with aCSF at 1.5 μL/min. Following an initial 100-min stabilization
period, 5 or 7 baseline samples were collected (20 min each) before local drug
application by reverse dialysis and then successive dialysate samples were collected.
In the experiments examining the effects on striatal DA release of electrical
stimulation of the MFB, rats (n= 4 animals per group) were anaesthetized with
chloral hydrate and 10 min fractions were collected (flow rate 3.0 μL/min). Bipolar
stimulating electrodes consisted of two stainless steel enamel-coated wires
(California Fine Wire, Grover Beach, CA, USA) with a diameter of 150 μm, a tip
separation of ~200 μm and in vitro impedances of 10–30 KΏ. A stimulating
electrode was stereotaxically implanted in the MFB (AP, −4.8; L, −1.0; and DV,
−8.2 mm) and secured to the skull with glue and dental cement. Constant
current electrical stimuli were generated with a Grass stimulation unit S-48
connected to a Grass SIU 5 stimulus isolation unit. Two stimulating conditions
were used: S1 (2.0 Hz, 0.1 mA, and 0.2 ms) and S2 (10 Hz, 0.1 mA, and 1 ms)77.
The concentration of DA in dialysate samples was determined by HPLC with
electrochemical detection (Hewlett Packard 1049, Palo Alto, CA, USA). Striatal
dialysates were collected into microvials containing 5 μL of 10 mM perchloric acid
and were rapidly injected into an HPLC. DA was amperometrically detected at
5–7.5 min with a LOD of 3 fmol/sample using an oxidation potential of +0.75 V.
Microdialysis results are expressed as femtomoles per fraction (uncorrected for
recovery) and are shown in figures as percentages of basal values (individual means
of 5–7 pre-drug fractions).
Tissular levels of DA and metabolites. DA, DOPAC (3,4-dihydroxyphenylacetic
acid), and HVA (homovanillic acid) contents were determined by HPLC with
electrochemical detection (+0.7 V) as previously described78. AAV-hTyr-injected
rats (n= 8) were killed at 4 m post-AAV injection and their brains quickly
removed and placed over a cold plate. Contralateral non-injected and ipsilateral
AAV-hTyr-injected striatum and substantia nigra from each animal were carefully
dissected out using a Rat Brain Matrix (TedPella, Spain), frozen on dry ice, and
kept at −80 °C until assayed. Tissues were homogenized in 300 or 500 μl (for
substantia nigra or striatum, respectively) of buffer containing 0.4 M perchloric
acid, 0.1% sodium metabisulphite, 0.01% EDTA, and 0.1% cysteine and centrifuged
at 12,000 × g for 30 min. Aliquots of supernatants were then filtered through
0.45 μm filters (Millex, Spain) and analyzed by HPLC as described. The mobile
phase consisted of 0.1 M KH2PO4, 1 mM octyl sodium sulfate, 0.1 mM EDTA
(pH 2.65), and 18% methanol. DA and their metabolites were separated on a
Mediterranea Sea column (C18, 3 μm, 10 cm × 6.4 mm) (Teknokroma, ref
TR010042, Spain).
UPLC-MS/MS analysis. AAV-hTyr-injected rats (n= 6) were killed at 1, 2, or 4 m
after AAV-hTyr injections and the brains quickly removed and placed over a cold
plate. Contralateral non-injected and ipsilateral AAV-hTyr-injected ventral mid-
brain from each animal were dissected out, frozen on dry ice, and stored at −80 °C
until analyzed. On the day of analysis, samples were homogenized with 300 µl/
hemisphere of 250 mM formic acid (FA) and protein concentrations determined by
bicinchoninic acid (BCA) Assay Kit (Pierce). Dopamine-1,1,2,2-d4 hydrochloride
(DA-d4) was added as internal standard (IS) to a final concentration of 500 nM and
samples were then centrifuged at 20,000 × g for 10 min at 4 °C, and the supernatant
was filtered using an Ostro™ protein precipitation and phospholipid removal plate
(Waters, USA) and injected in the UPLC-MS/MS system twice to analyze MIX1
(dopamine, 3-methoxytyramine and oxidized dopamine) and MIX2 (3,4-dihy-
droxyphenylacetic acid). A Waters Acquity™ UPLC system was coupled with a
Xevo TQ-S triple quadrupole mass spectrometer with electrospray ionization
interface (Waters). Instrument control, data acquisition, and analysis were per-
formed using MassLynx V4.1 (Waters). The chromatographic separation was
performed on a Waters Acquity™ HSS T3 (1.8 μm; 2.1 × 100 mm) column coupled
to a Acquity™ HSS T3 VanGuard (100 Å, 1.8 µm, 2.1 mm × 5mm) pre-column and
a Acquity™ UPLC in-line filter (Waters). Column temperature was set at 40 °C
and samples were maintained at 6 °C in the thermostatic autosampler. The mobile
phase consisted of solvent A (methanol 100%) and solvent B (25 mM FA in water)
at a flow of 0.4 ml/min with the following gradient profile: 0.5% B maintained for
0.5 min, 8% B at 2.6 min, 55% B at 2.9 min, 60% B at 3.3 min, 80% B at 4.3 min,
90% B at 4.4 min and maintained for 0.5 min, and 0.5% B at 5 min followed by
1 min of equilibration. The mass spectrometer detector operated under the
following parameters: source temperature 150 °C, desolvation temperature 450 °C,
cone gas flow 50 L/hr, desolvation gas flow 1100 L/h and collision gas flow 0.15 ml/
min. Argon was used as the collision gas. The capillary voltage was set at 0.5 kV for
MIX1 and at 2 kV for MIX2 detection. The electrospray ionization source was
operated in both positive and negative modes, depending on the analyte. Multiple
Reaction Monitoring (MRM) acquisition settings for the targeted metabolites are
summarized in Supplementary Table 3. Oxidized dopamine was detected using the
following parameters: MRM transition (m/z) 149.61 > 121.91; cone voltage 25 V;
collision energy 25 eV; capillary voltage kV 0.5 kV. Two independent weighted
(1/x) linear regression curves excluding the origin were constructed for oxidized
dopamine with 5 calibration points spiked to ventral midbrain samples of control
rats. Linearity was considered acceptable if R2 ≥ 0.99 and more than 75% of the
residuals had a variability smaller than 20%. With respect to sensitivity, the limit
of detection (LOD) was defined as the concentration level with the signal-to-noise
ratio at 3, and the limit of quantification (LOQ) was defined as the concentration
level with the signal-to-noise ratio at 10 (see parameters in Supplementary Table 4).
They were calculated as 3 or 10 times the ratio between the standard deviation
of the Y-intercept value and the slope of each calibration curve, respectively.
Samples with a concentration between LOD and LOQ or bigger than LOQ were
considered acceptable; samples with a concentration lower than LOD were con-
sidered as 0 nM. Oxidized dopamine standard (0.5 mM) was freshly prepared as
previously described44,79. In brief, 100 µl of 1 mM dopamine dissolved in water was
mixed with 100 µl of 2 mM KIO4 dissolved in 100 µM aqueous ammonium acetate
buffer (pH 5.8) at RT with vigorous shaking for 1 min. Successive dilutions were
made in 25 mM FA.
Human post-mortem brain tissue. Paraffin-embedded midbrain sections (5 µm)
from idiopathic Parkinson’s disease patients (PD; n= 10), incidental Lewy body
disease cases (ILBD; n= 3) and age-matched control individuals (n= 6) were
provided by the Neurological Tissue BioBank at IDIBAPS-Hospital Clinic (Bar-
celona). Detailed information about these subjects is provided in Supplementary
Table 1. Informed written consent was obtained from all human subjects. All
procedures were conducted in accordance with guidelines established by the BPC
(CPMP/ICH/135/95) and the Spanish regulation (223/2004) and approved by the
Vall d’Hebron Research Institute (VHIR) Ethical Clinical Investigation Committee
[PR(AG)370/2014]. For intracellular NM quantification in human brain samples,
three different clinical diagnosis groups were evaluated: control subjects (1436 cells
analyzed in a total of 6 cases), ILBD cases (640 cells analyzed in a total of 3 cases)
and PD patients (644 cells analyzed in a total of 10 cases). Standard H&E staining
was performed on 5-µm-thick paraffin-embedded SNpc sections for each subject.
Identification of DA neurons was ascertained by the visualization of unstained NM
pigment. For each section, all NM-positive neurons were examined at an objective
magnification of ×20. Quantifications of intracellular NM optical density were
performed as above by an investigator blinded to the experimental groups.
Endogenous brain tyrosinase gene expression. Total RNA from human post-
mortem substantia nigra brain tissue (n= 8 control individuals; mean age at death
77 ± 3.7 years; detailed information for each case can be found in Supplementary
Table 1) was extracted using miRNeasy Micro Kit (Qiagen). Total RNA from
mouse (n= 5) and rat (n= 8) dissected ventral midbrain tissue was extracted using
the mirVana PARIS RNA and Native Protein Purification Kit (Thermo Fisher
Scientific). RNA concentration was determined using a NanoDrop ND-1000
Spectrophotometer and RNA integrity was assessed by running the samples on
an Agilent RNA 6000 Nano chip on an Agilent 2100 BioAnalyzer (Agilent
Technologies). For human samples, 10 ng of total RNA were retrotranscribed
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and amplified using the Ovation Pico WTA System V2 (Nugen Technologies,
Inc.). For mouse and rat, 0.5 µg of total RNA were retrotranscribed using oligo(dT)
12–18 primers (Thermo Fisher Scientific) and SuperScript™ III Reverse Tran-
scriptase kit (Thermo Fisher Scientific). Quantitative real-time PCR (qPCR)
was performed with 45–50 ng of cDNA per well in technical duplicates mixed
with Taqman Gene Expression Master Mix (Applied Biosystems) and Taqman
gene expression assays (human tyrosinase (Tyr) Hs00165976_m1; rat Tyr
Rn01511409_m1; mouse Tyr Mm00495818_m1; human tyrosine hydroxylase (TH)
Hs00165941_m1; rat TH Rn00562500_m1; mouse TH Mm00447557_m1; Applied
Biosystems) using standard procedures in a 7900HT Fast Real Time Instrument
(Applied Biosystems). Thresholds cycles (Cts) for each target gene were normalized to
an endogenous reference gene (Gapdh Mm99999915_g1 / Rn01775763_g1, Rpl19
Mm02601633_g1 / Rn00821265_g1 or Rplp0 Mm00725448_s1 / Rn03302271_gH for
rodent samples, and HPRT1 Hs02800695_m1, GUSB Hs00939627_m1, or RPLP0
Hs04189669_g1 for human samples). Water was included in the reaction as a non-
template (negative) control. The relative expression was calculated with the
ΔCt-method. Serial dilutions of a DNA fragment corresponding to the full-length
hTyr transcript, obtained by enzymatic digestion from a pCDNA4-hTyr plasmid
(kindly provided by T. Hasegawa), were used as template for a qPCR reaction of
3 replicates for each dilution with the assay Hs00165976_m1 to specifically
detect human Tyr expression and correlate the number of Tyr molecules and
the Ct values obtained.
TR5TY6 neuroblastoma cell line. A stable inducible SH-SY5Y cell line expressing
human tyrosinase (TR5TY6) under the transcriptional control of the T-Rex TM
Tet-On system (Invitrogen) was provided by Dr. T. Hasegawa (Department of
Neurology, Tohoku University, Sendai, Japan). Cell line was confirmed negative for
mycoplasma contamination by routine PCR analysis. Cells were maintained in low-
glucose (1 g/l) Dulbecco’s modified Eagle’s (DMEM) (Gibco) medium with peni-
cillin/streptomycin, and the appropriate selection of antibiotics (7 µg/mL blas-
ticidin and 300 µg/mL Zeocin, both from Life Technologies). Medium was
supplemented with tetracycline-free fetal bovine serum (FBS) (Clontech) to avoid
unwanted expression of the transgene. TR5TY6 cells were seeded for aSyn-PLA,
flow cytometry and immunoblot analysis at 2.5 × 105 or 106 cells/plate in 24-, 12-,
or 6-well plates, respectively. For PLA, cells were grown onto 12-mm slides coated
with 50 µg/ml poly-D lysine (Sigma-Aldrich). Unless stated otherwise, 24 h after
seeding cells were differentiated with 10 µM retinoic acid (RA) (Sigma-Aldrich) for
3 days, followed by 80 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) (Sigma-
Aldrich) for 3 extra days prior to hTyr induction with 2 µg/ml doxycycline (Sigma-
Aldrich) for up to 6 days. Intracellular NM in differentiated hTyr-induced TR5TY6
cells was quantified at the indicated times as follows: (i) optical densitometry in
fixed cells, examined under transmitted light at an objective magnification of ×40;
each slide was divided in a grid, images were taken from 25 fields (50% coverage)
and analyzed as described above for rat sections; (ii) spectrophotometry, by
diluting 2 µl of cell lysate in a total volume of 200 µl PBS and measuring the
absorbance at 405 nm with a ELx800 Absorbance Microplate Reader (BioTek
Instruments, USA).
Immunoblot. Differentiated TR5TY6 cells induced for 0, 1, 3, and 6 days were
homogenized in RIPA buffer supplemented with protease inhibitors (Roche) and
cell extracts clarified by centrifugation at 10,000 × g for 10 min at 4 °C. Protein
concentrations were quantified using the BCA method and subjected to SDS-
PAGE. Proteins were resolved in 10 or 15% polyacrylamide gels and transferred
onto 0.45 µm nitrocellulose membranes (Amersham). Blocking with 5% milk
powder in PBS was followed by overnight incubation at 4 °C with the primary
antibodies mouse anti-tyrosinase (1:2000, Thermo Fisher Scientific, Cat#MS-800-
P1), rabbit anti-Lamp1 (1:250, GeneTex, Cat#GTX19294), rabbit anti-LC3 (1:1000,
Novus Biologicals, Cat#NB100-2220), guinea pig anti-p62 (1:1000, Progen,
Cat#GP62-C) or mouse anti-β-actin (1:5000, Sigma-Aldrich, Cat#A5441). Incu-
bation with the secondary antibodies donkey anti-rabbit, sheep anti-mouse (both
1:5000, from Amersham), and goat anti-guinea pig (1:1000, Santa Cruz Bio-
technology) was performed for 1 h at RT. Band densitometry, normalized to
β-actin expression, were measured using ImageJ image analysis software.
Optical microscopy for NM. Cells fixed with 4% paraformaldehyde for 30 min at
4 °C were blocked with 3% NGS (Atom) and 0.1% (vol/vol) Triton X-100 (Sigma-
Aldrich) in PBS solution. Hoechst 33342 (1:10,000, Thermo Fisher Scientific)
was used for nuclei counterstain for 1 h at RT in 2% (vol/vol) NGS. Cells were
coverslipped using Dako Cytomation Fluorescent Mounting Medium (Dako)
and images acquired using standard filter sets either with an Olympus FSX100
microscope with a DP72 incorporated camera and FSX-BSW visualization software
(Olympus, Germany) or with an Olympus FluoView™ FV1000 confocal microscope
and FV10-ASW 4.2 visualization software.
aSyn-proximity ligation assay. TR5TY6 cells were induced for hTyr expression
for 0, 3, and 6 days and fixed in 4% paraformaldehyde for 30 min at 4 °C. Custom
PLA probes were prepared by conjugating 20 µl of the Ab-2 mouse monoclonal
aSyn antibody (1 mg/ml) (Thermo Scientific, Cat#MS-1572) with one vial of
Duolink In Situ Probemaker containing either PLUS (Sigma-Aldrich,
Cat#DUO92009) or MINUS (Sigma-Aldrich, Cat#DUO92010) oligonucleotides.
PLA assay was done using the Duolink in Situ Detection Reagents Red assay
protocol (Sigma-Aldrich, Cat#DUO92008) following manufacturer’s instructions.
Briefly, fixed cells were incubated with 3 drops of tempered blocking solution for
30 min at RT, shaking at low speed. Slides were then washed with PBS once and
each slide incubated overnight at 4 °C with 20 µl of a mixture of both PLUS
and MINUS antibody-conjugated oligonucleotide PLA probes in a humidity
chamber. Ligation was done for 30 min at 37 °C, followed by amplification for
90 min at 37 °C, both in a humidity chamber as well. Nuclei counterstaining was
done with Hoechst 33342 (1:10,000, Thermo Fisher) for 2 min. Slides were then
washed three times with Washing Buffer B for 10 min each, mounted using
fluorescent mounting medium (Dako) and visualized using an Olympus FSX100
microscope with a DP72 incorporated camera and FSXBSW visualization software
(Olympus, Germany). Quantification of aSyn-PLA signal was performed by mea-
suring intracellular pixel intensity values for individual cells (OFF, n= 153; 3d,
n= 201; 6d, n= 135) in all acquired images using ImageJ.
Mitochondrial respiration. Oxygen consumption rate (OCR) was measured in
TR5TY6 cells using an XF24 Extracellular Flux Analyzer (Seahorse Biosciences,
Agilent Technologies, USA). Briefly, 105 cells/well were plated in XF24 microplates,
differentiated, and induced for hTyr expression for 0, 3, and 6 days as described
above. 24 h prior to the experiment, the instrument was calibrated following the
manufacturer’s instructions. Cells were incubated for 1 h in 675 µl respiration
medium (DMEM base, Sigma-Aldrich, supplemented with 5.5 mM glucose, 31.6
mM NaCl, Phenol Red, and 2 mM GlutaMax, Thermo Fisher Scientific) at 37 °C in
a CO2-free incubator. Following overnight calibration of the sensor cartridge, plates
were run on the Seahorse XF24 flux analyzer to calculate OCR. Four initial mea-
surements, corresponding to basal oxygen consumption (routine state, without
respiratory chain inhibitors), were performed per experiment, with each mea-
surement cycle consisting of 4 min agitation, 2 min stand, and 1.5 min measure-
ment. After each run, cells were lysed in RIPA buffer (150 mM NaCl, 10 mM Tris,
pH 7.2, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA, 1 mM PMSF)
and OCRs normalized to protein concentration, with measurements made
using BCA. Four independent experiments were performed, each in triplicates.
Intracellular protein degradation assay. Total protein degradation in differ-
entiated TR5TY6 cells was measured by pulse-chase experiments as previously
described, with some modification80. Briefly, confluent TR5TY6 cells were induced
for hTyr expression for 0, 3, and 6 days and labeled with [3H]-valine (2 μCi/ml;
Hartmann Analytic) at 37 °C for 24 h. Cells were then extensively washed with
medium and returned in complete growth medium containing an excess of unla-
beled valine for a chase period of 5 h. Cells were cultured with or without lysosomal
inhibitors (100 µM leupeptin, 10 µM pepstatin A, and 10 µM E64d) to assess the
contribution of the lysosomal system to protein degradation. Triplicated aliquots of
the medium at the indicated time were collected and precipitated with 20% tri-
chloroacetic acid. Acid-soluble fractions were collected after vacuum filtration
using a Millipore manifolder and were quantified using a LS6500 liquid scintilla-
tion counter (Beckman Coulter). Cells were then lysed with 0.1% NaOH and 0.1%
Triton X-100, and the total protein concentration measured for normalization
purposes and to measure total surviving cells at the end of the induction times.
Proteolysis was measured using a LS6500 liquid scintillation counter (Beckman
Coulter) and expressed as the percentage of the initial acid insoluble radioactivity
(total protein) transformed to acid-soluble radioactivity (amino acids and small
peptides) at the end of the incubation time. Lysosomal proteolysis was calculated
as the proteolysis sensitive to lysosomal inhibitors. Three independent pulse and
chase experiments were performed.
Ubiquitin-proteasome system activity. Differentiated TR5TY6 cells induced for
hTyr expression for 0, 3, and 6 days were lysed in 10 mM tris pH7.8, 1 mM EDTA,
5 mM Mg2Cl, 0.1% Triton X-100. Chymotrypsin-like activity was determined
using 10 µg of total cell extracts in a total volume of proteasome activity buffer (10
mM tris pH7.8, 1 mM EDTA, 0.5 mM DTT, 5 mMMg2Cl, 2 mM ATP), incubating
for 60 min at 37 °C with 0.5 mM of the fluorogenic substrate Z-Leu-Leu-Glu-AMC
(Z-LLE-AMC) (Enzo, Cat# BML-ZW9345). As control, all reactions were also
performed in parallel in the presence of 50 µM MG132 inhibitor (Enzo BML-
PI102). Fluorescence intensity was quantified by using the Flx800 multi-detection
microplate reader (BioTek) with excitation and emission wavelengths at 360 and
460 nm, respectively. UPS activity at different time points is presented as percen-
tage of the control (OFF cells), and represent the mean of three independent
experiments each performed in triplicates.
TFEB-induced lysosomal exocytosis (dot blot). TR5TY6 cells were transiently
transfected using Lipofectamine ™3000 Transfection reagent (Thermo Fisher Sci-
entific) according to the manufacturer’s instructions. Briefly, 5 × 104 cells were
seeded into 6-well plates the day before transfection with 2.5 µg of the construct
pCIP-Flag-TfebAA (a gift from Reuben Shaw, Addgene plasmid Cat#79014)) and
5 µl of P3000 reagent. Transfected cells were harvested with medium, centrifuged at
800 × g at RT and 150 µl of culture medium were spotted onto a nitrocellulose
membrane (GE Healthcare) using the Mini-Fold®-1 Dot-Blot system (Whatman,
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Inc.). The membrane was blocked in 5% non-fat milk powder in PBS for 1 h at RT
and incubated overnight at 4 °C with mouse anti-Lamp2 (H4B4) antibody (1:1000,
Santa Cruz Biotechnology, Inc. Cat#sc-18822). Incubation with anti-mouse sec-
ondary antibody coupled to horseradish peroxidase (1:1000 in 5% non-fat milk
powder/PBS; GE Healthcare, #NXA931V and #NA934V) was performed for 1 h at
RT, followed by repeated washings with PBS. Immunoreactive spots were visua-
lized using SuperSignal Femto Chemiluminescent Substrate (Pierce) according to
the manufacturer’s instructions and quantified on an ImageQuant RT ECL imaging
system (GE Healthcare). Lysosomal exocytosis at different time points is presented
as percentage of the non-TFEB-transfected cells, and represent the mean of three
independent experiments run in duplicates.
Cell metabolic activity and ROS production. Metabolic activity was measured in
differentiated TR5TY6 induced for hTyr expression for 0, 3, and 6 days. Briefly,
cells were centrifuged at 800 × g for 5 min at 4 °C, resuspended in PBS and incu-
bated at 37 °C and 5% CO2 for 15 min with 10 µM C12-resazurin (Thermo Fisher
Scientific). C12-Resazurin is readily reduced in metabolically active cells to red-
fluorescent C12-resofurin (λexcitation= 563 nm; λemission= 587 nm). To quantify
the production of ROS, TR5TY6 cells were loaded with freshly prepared 25 µM
CellROX Green Reagent (λexcitation= 485 nm; λemission= 520 nm) (Thermo
Fisher Scientific), a fluorescent dye that measures ROS production independently
of its potential origin or location, for 30 min at 37 °C and 5% CO2. Cells were
afterwards washed and harvested for flow cytometry analysis. Fluorescence data
acquisition was performed by recording 10,000 events in an LSR Fortessa flux
cytometer (BD Biosciences) and analyzed with FCS Express Version 4 software.
Intact cells were gated in an FSC/SSC plot to exclude small debris. Cell metabolic
activity and ROS production at different time points are presented as mean
fluorescence intensity, and represent the mean of three independent experiments
each performed in triplicates.
Transmission electron microscopy. (i) Animals: rats were perfused transcardially
with 4% PFA and 0.1% glutaraldehyde (Merck Millipore) in Dulbecco’s phosphate-
buffered saline (DPBS, Gibco). Brains were removed and post-fixed for 4 h at 4 °C
in the same fixative, washed in DPBS and sectioned into 100-μm-thickness slices
using a vibratome (Leica, Germany). Free-floating sections were blocked in 0.1%
Triton X100 and 10% NGS in PBS for 1 h at RT, incubated with primary antibody
rabbit anti-TH (1:1000, Calbiochem) in PBS, a secondary goat anti-rabbit antibody
conjugated to biotin (1:1000, Vector Laboratories), and visualized using Immu-
nopure ABC Peroxidase staining kit (Thermo Fisher Scientific) and DAB Perox-
idase Substrate kit (Vector laboratories). The sections were post-fixed in 3%
glutaraldehyde and in 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4),
dehydrated in ethanol, and embedded in Spurr’s epoxy resin (Sigma-Aldrich).
Survey sections (2 μm) and ultra-thin sections (around 70 nm) were cut with a
diamond knife (Diatome) using an ultramicrotome Ultracut E (Reichert-Jung).
Ultrathin sections were collected onto formvar-coated copper/gold grids, coun-
terstained with 2% uranyl acetate and led citrate, and examined in a JEOL 1010
(tungsten filament) transmission electron microscope. Images were acquired with
an Orius CCD camera using Digital Micrograph software (GATAN). (ii) Post-
mortem human brain: human control samples were initially fixed in formaldehyde
and post-fixed in 3% glutaraldehyde, embedded in epoxy resin. Semi-thin and
ultra-thin sections were processed as above. Sections were examined at a Zeiss 10 A
transmission electron microscope. (iii) TR5TY6 cells: confluent 10-cm culture
plates containing differentiated TR5TY6 cells induced for hTyr expression for 0, 1,
3, and 6 days were washed with a fixative solution containing 2.5% glutaraldehyde
(Merck Millipore) in 0.1 M DPBS and then fixed for 1 h at RT in the same fixative.
Cells were afterwards gently scraped and centrifuged at 300 × g to get a visible pellet
that was kept in fixative at 4 °C until forward processing. Cell pellets were post-
fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4), dehydrated in
ethanol, and embedded in Spurr’s epoxy resin (Sigma-Aldrich). Semi-thin and
ultra-thin sections, counterstain, and image acquisition were done as described
above for rat sections.
Statistics. All values are expressed as the mean ± standard error of the mean
(SEM). Statistical comparisons were performed with SigmaStat software (v4, Systat
Software Inc, USA) using the appropriate statistical tests, as indicated in each figure
legend. No statistical methods were used to pre-determine sample size but our
sample sizes are equivalent to those reported in previous similar publications81.
Outlier values were identified by the Grubbs’ test (i.e. Extreme Studentized Deviate,
ESD, method) using GraphPad Prism software (v6, GraphPad Software Inc, USA)
and excluded from the analyses when applicable. Selection of the pertinent sta-
tistical test for each experiment was determined after formally testing for nor-
mality. Accordingly, differences among means were analyzed either by 1- or 2-way
analysis of variance (ANOVA), Kruskal–Wallis ANOVA on ranks, two-tailed t-test
or Mann–Whitney rank sum test, as appropriate. When ANOVA showed sig-
nificant differences, pairwise comparisons between means were subjected to
Student–Newman–Keuls, Dunn’s or Holm-Sidak post-hoc testing for multiple
comparisons, as appropriate. In all analyses, the null hypothesis was rejected at
the 0.05 level.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data relevant to the study is available from the authors on reasonable request.
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